University of Pennsylvania

ScholarlyCommons
Dental Theses

Penn Dental Medicine

Summer 8-5-2014

Characterization of Mandible and Femur Canine Mesenchymal
Stem Cells: A Pilot Study
Juan M. Bugueno
University of Pennsylvania, ddsjb@hotmail.com

Follow this and additional works at: https://repository.upenn.edu/dental_theses
Part of the Dentistry Commons, and the Small or Companion Animal Medicine Commons

Recommended Citation
Bugueno, Juan M., "Characterization of Mandible and Femur Canine Mesenchymal Stem Cells: A Pilot
Study" (2014). Dental Theses. 3.
https://repository.upenn.edu/dental_theses/3

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/dental_theses/3
For more information, please contact repository@pobox.upenn.edu.

Characterization of Mandible and Femur Canine Mesenchymal Stem Cells: A Pilot
Study
Abstract
Mesenchymal stem cells (MSCs) are emerging donor grafts for bone regeneration in dentistry. MSCs are
phenotypically and functionally skeletal site- specific based on extensive studies using human and rodent
MSCs but there is paucity of information on canine MSCs (cMSCs) and their regenerative applications in
veterinary dentistry. We hypothesized that cMSCs are functionally skeletal-site specific and that mandible
cMSCs (M-cMSCs) are highly osteogenic relative to femur cMSCs (F-cMSCs). Trabecular bone samples
were obtained from mandible and femur of 2 healthy beagle dogs (ages: 3 weeks, females). Primary McMSCs and F-cMSCs were established in culture. Using early passage cells, colony-forming units (CFU),
cell proliferation and population doubling capacity were assessed. Using established induction culture
conditions, in vitro osteogenesis, chondrogenesis, adipogenesis, and neurogenesis were also assessed.
Western blotting and real time PCR were used to assess the following osteogenic markers: alkaline
phosphatase (ALP), bone sialoprotein (BSP), osteocalcin (OCN) and osteopontin (OPN). Chondrogenesis
was assessed using pellet culture method and histologic sections were stained with Alcian blue;
adipogenically induced-cultures were stained with Oil Red O. Neural differentiation was evaluated using
morphological analysis and immunostaining to nestin and βIII-tubulin antibodies. Furthermore, in vivo
osteogenesis was assessed using the mouse model of in vivo bone regeneration. Transplants were
harvested at 6, 8 and 12 weeks for histological analysis.The M-cMSCs demonstrated 1.5 to 2 fold
increases in cell proliferation (p =0.006) and life span (five more passages of survival) relative to FcMSCs. Similar pattern was displayed by M-cMSCs based on expression levels of BSP (14 days p=0.05),
ALP (14 days p= 0.004) and OCN (14 days p= 0.03) but OPN levels were not significantly different.
Adipogenesis based on number of stained lipid droplets per unit area in M-cMSCs was significant higher
than F-cMSCs (p=0.007) and chondrogenic response was also significant higher in M-cMSCs compared
with F-cMSCs (4 weeks p= 0.009). Canine MSCs induced substantial in vivo bone formation. The canine
MSCs phenotypic and functional properties are site-dependent as the M-cMSCs were apparently more
responsive to multi-lineage differentiation relative to F-cMSCs. While the sample size in this study is
limited, our findings are still consistent with previous studies using human, mouse and rat MSCs for siteto-site comparative characterizations (Akintoye et al, 2006; Yoshimura et al, 2007; Aghaloo et al, 2010; Lee
et al, 2011). Additionally, it is imperative to further confirm these in a larger sample size and in other dog
breeds since dogs exhibit an extremely wide range of body physique. New information will advance our
understanding of pre-clinical applications of orofacial MSCs as donor graft materials for oral bone
regeneration.
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ABSTRACT

Mesenchymal stem cells (MSCs) are emerging donor grafts for bone
regeneration in dentistry. MSCs are phenotypically and functionally skeletal sitespecific based on extensive studies using human and rodent MSCs but there is
paucity of information on canine MSCs (cMSCs) and their regenerative
applications in veterinary dentistry. We hypothesized that cMSCs are functionally
skeletal-site specific and that mandible cMSCs (M-cMSCs) are highly osteogenic
relative to femur cMSCs (F-cMSCs).
Trabecular bone samples were obtained from mandible and femur of 2 healthy
beagle dogs (ages: 3 weeks, females). Primary M-cMSCs and F-cMSCs were
established in culture. Using early passage cells, colony-forming units (CFU), cell
proliferation and population doubling capacity were assessed. Using established
induction

culture

conditions,

in

vitro

osteogenesis,

chondrogenesis,

adipogenesis, and neurogenesis were also assessed. Western blotting and real
time PCR were used to assess the following osteogenic markers: alkaline
phosphatase (ALP), bone sialoprotein (BSP), osteocalcin (OCN) and osteopontin
(OPN). Chondrogenesis was assessed using pellet culture method and histologic
sections were stained with Alcian blue; adipogenically induced-cultures were
stained with Oil Red O. Neural differentiation was evaluated using morphological
analysis and immunostaining to nestin and βIII-tubulin antibodies. Furthermore,
in vivo osteogenesis was assessed using the mouse model of in vivo bone
regeneration. Transplants were harvested at 6, 8 and 12 weeks for histological
analysis.
The M-cMSCs demonstrated 1.5 to 2 fold increases in cell proliferation (p =
0.006) and life span (five more passages of survival) relative to F-cMSCs. Similar
pattern was displayed by M-cMSCs based on expression levels of BSP (14 days
p= 0.05), ALP (14 days p= 0.004) and OCN (14 days p= 0.03) but OPN levels
were not significantly different. Adipogenesis based on number of stained lipid
droplets per unit area in M-cMSCs was significant higher than F-cMSCs (p=
vi

0.007) and chondrogenic response was also significant higher in M-cMSCs
compared with F-cMSCs (4 weeks p= 0.009). Canine MSCs induced substantial
in vivo bone formation.
The canine MSCs phenotypic and functional properties are site-dependent as the
M-cMSCs were apparently more responsive to multi-lineage differentiation
relative to F-cMSCs. While the sample size in this study is limited, our findings
are still consistent with previous studies using human, mouse and rat MSCs for
site-to-site comparative characterizations (Akintoye et al, 2006; Yoshimura et al,
2007; Aghaloo et al, 2010; Lee et al, 2011). Additionally, it is imperative to further
confirm these in a larger sample size and in other dog breeds since dogs exhibit
an extremely wide range of body physique. New information will advance our
understanding of pre-clinical applications of orofacial MSCs as donor graft
materials for oral bone regeneration.
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1 INTRODUCTION

1.1 Development of craniofacial, axial, and appendicular skeleton
One of the hallmarks that distinguish vertebrates from invertebrates is the
formation of bones, their associated cartilages, and joints. The first sign of
skeletal development is formation of mesenchymal condensations, in which
mesenchymal progenitor cells aggregate at future skeletal locations. These
mesenchymal cells arise from different cell lineages. The mesenchyme that gives
rise to the axial skeletal elements (i.e., vertebral column, ribs, and sternum)
originates from the sclerotomal portion of the mesodermal somites, whereas the
appendicular skeleton (pectoral girdles, upper and lower limbs, pelvis) is derived
from the mesenchyme of the lateral plate mesoderm. The developmental origin
of the craniofacial skeleton is more complex. Some cranial bones (e.g., the
bones making up the roof and much of the base of the skull) are mesodermal in
origin, but the facial bones and some other cranial bones arise from
mesenchyme derived from the ectodermal neural crest. Skeletal formation
progresses through two major mechanisms: intramembranous and endochondral
ossification. The type of ossification and anatomic properties of the bones are
determined by the location of each skeletal element. Consequently, the deep
skeletal parts of the body typically first appear as cartilaginous models of the
bones that will ultimately be formed. At specific periods during embryogenesis,
the cartilage is replaced by true bone through the process of endochondral
ossification. By contrast, during intramembranous ossification, the superficial
1

bones of the face and skull are formed by direct ossification of mesenchymal
cells without an intermediate cartilaginous stage (Helms and Schneider, 2003;
Carlson, 2014; Clifford et al, 2013).
Mammalian craniofacial skeleton is a complex structure of bones and cartilages
that is generally divided in two main components: the neurocranium and the
viscerocranium. The neurocranium encloses and supports the brain and cranial
sense organs. It comprises the skull vault and base. The viscerocranium
provides the structural scaffolding for sight, olfaction and, together with the
mandible, mastication (Lawson, 2008). Frontal, parietal, and a part of the
occipital bones form the skull vault. The frontal bones are developed from cranial
neural crest cells (NCCs), while others are mostly derived from mesoderm cells.
These bones are interconnected by cranial sutures which are the primary sites of
osteogenesis during skull development. The skull vault is formed through
intramembranous ossification. Ethmoid, sphenoid, basioccipital bones, and parts
of the temporal bones build the cranial base. The anterior-most skull base is
derived from cranial NCCs, while the posterior region comes from paraxial
mesoderm. Contrasting with other craniofacial skeletal components, bones from
the skull base develop through endochondral ossification (Clifford et al, 2013;
McBratney-Owen et al, 2008).
Early craniofacial development is characterized by several massive migrations
and displacements of cells and tissues. Bones that come into being the
viscerocranium are derived from cranial NCCs. These cells develop in dorsal
midline ectoderm of the midbrain and the rhombencephalon (or hindbrain), in a
2

number of transversal swellings called rhombomeres, undergo an epithelial to
mesenchymal transition, delaminate, and then migrate ventrolaterally between
the ectoderm and endoderm. While the rostral cranial NCCs develop the
frontonasal skeleton and the skull vault, NCCs from each rhombomere, take
distinct pathways to populate different pharyngeal arches (PA). NCCs from
rhombomeres 1 and 2 migrate into the first pharyngeal arch and the frontonasal
process. This structure gives rise to the incus and malleus of the ears, the
mandible, and the maxilla. The frontonasal process gives rise to tissues in the
upper half of the face, including the forehead, nose, eyes, and philtrum. NCCs
from rhombomeres 3 and 4 migrate into the second pharyngeal arch, which gives
rise to the stapes bone of the middle ear, the styloid process of temporal bone,
and a part of the hyoid bone. The third arch gives rise to structures related to the
hyoid bone and upper pharynx, while the fourth arch forms certain muscles and
cartilages of the larynx and lower pharynx (Fig. 1) (Helms, 2003; Carlson, 2014;
Clifford, et al, 2013).

3

Figure 1

Cranial NCC migration and NCC-derived cartilage and bones: (A) NCCs go through
epithelial-mesenchymal transition and migrate ventrolaterally from rhombomeres (R)
to populate pharyngeal arches (PA). NCCs in R3 and R5 merge with streams of
NCCs from neighboring rhombomeres. Bones and cartilage derived from each PA
are listed. (B) Facial and frontal bones are derived from NCCs. Posterior skull base
and vault are mostly derived from somatic mesoderm.
Adapted from Clifford et al, 2013.Primer on the metabolic bone diseases and
disorders of mineral metabolism.

Development of the axial and appendicular skeleton: the intra-embryonic
mesoderm of each side of the forming notochord and neural tube thickens to
form a longitudinal column of para-axial mesoderm. By the end of the third week
of the embryonic development, the para-axial mesoderm divides into paired
bodies called somites, located bilaterally to the neural tube. At the fourth week,
ventromedial

cells

migrate

toward

the
4

notochord

to

form

sclerotome

(mesenchyme). Proteins secreted by notochord and neural tube floor plate
induce sclerotome formation. Once induced, sclerotome cells express the
transcription factor PAX1 that initiates a cascade of cartilage and bone forming
genes for vertebral column development. The first pair of somites develops a
short distance posterior to the cranial end of the notochord, and the rest of the
somites develop caudally. Around 38 pairs of somites form during the somite
period of development, from days 20 to 30. The final number is 42 to 44 pairs.
Each somite becomes differentiated into ventromedial sclerotome (for vertebrae
and ribs), myotome (muscles) and dermatome (skin). In addition to the paraxial
region, the mesoderm forms lateral somatic plates that form all cartilages and
bones of appendicular skeleton. By the end of week four, limb buds are visible
and each one consists of a mass of mesenchyme derived from the somatic
mesoderm, covered by a layer of ectoderm. At the tip of each limb bud,
ectodermal cells form an apical ectodermal ridge, which promotes growth and
development of the limbs in the proximo-distal axis (Moore, 2008) (Fig. 2 and 3).

5

Figure 2

A third week human blastocyst with three germ layers: movement of
the mesodermal cells between 17 and 21 days of development.
Adapted from Copyright © 2007 Lippincott Williams & Wilkins

Figure 3

Skeletal development vertebral column and limbs: origin of axial and
appendicular skeleton from scleretome and lateral plate mesoderm.
Adapted from Mark, H. Skeletal development: vertebral column and limbs, University of
Toledo
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1.2 Bone tissue

1.2.1 General features
Bone is one of the most metabolically active connective tissues in the vertebrate
organisms. It is a highly vascularized and well innervated mineralized tissue.
Bone provides structural support and facilitates mobility by providing levers for
muscle attachment. Bone also protects vital structures, serves as reservoirs for
minerals and acid-base homeostasis, and is a vital site for hematopoiesis (Buck,
et al, 2011; Fernandez, et al, 2006). Each particular bone of any organism
constantly experiences modeling during life to adapt to changing biomechanical
forces, as well as remodeling to remove old, micro-damaged bone and replace it
with new, mechanically stronger bone to help preserve bone strength (Clarke,
2008).
The two main structural types of bones are cortical and cancellous or trabecular
bone. The ratio of cortical to trabecular bone is different for each bone and
skeletal site within a specific bone. For example, this ratio is 50:50 in the human
femoral head (Clarke, 2008). Cortical bone, with a porosity of 5-10%, provides
bone its compressive strength as well as a maximum resistance to torsion and
bending (Buck, et al, 2011). Cancellous bone has a high metabolic activity and
remodeling rate. It can adapt readily to mechanical stimuli and changes in
loading forces (Buckwalter, et al, 1995). Cortical and trabecular bone are
normally formed in a lamellar pattern in which collagen fibrils are tightly packed in
sheets with uniform distribution of osteocytes and bone matrix. The mechanism
7

by which osteoblasts lay down collagen fibrils in a lamellar pattern is unknown,
but lamellar bone has a significant strength as a result of the alternating
orientations of collagen fibrils (Buck et al, 2011; Fernandez et al, 2006; Clarke,
2008). The arrangement of these lamellae determines whether the bone is
cortical or cancellous. In the cortical bone, lamellae are concentric and parallel to
the long axis of the bone. They surround central Haversian canals forming the
major structural unit of cortical bone: the osteon. Multiple cell processes, or
canaliculi, from osteocytes extend in a radial pattern from the central canal,
allowing diffusion of nutrients through the bone matrix (Jepsen, 2009; Buck et al,
2011). Cancellous or trabecular bone is formed by a network of bone lamellae,
delimiting areolar cavities inside which the bone marrow is found. In this bone,
lamellae are arranged in semicircular shapes called packets, and this kind of
structure gives cancellous bone remarkable surface area which is an important
feature in the rate of bone graft incorporation (Clarke, 2008; Jepsen, 2009).
The periosteum is a fibrous connective tissue sheath that covers the external
surface of bone and is attached to the outer cortex via thick collagenous fibers
called “Sharpey’s fibers”. It contains blood vessels, nerve fibers, and osteoblasts
and osteoclasts. Additionally, it provides an attachment site for some ligaments
and tendons. The periosteum is a structure with two layers: a dense, hypocellular
outer layer that continues into joint capsules and interconnects adjacent bones
and an inner layer, the cambium, which contains osteoprogenitor cells and a
vascular plexus. The endosteum is a membranous structure covering the inner
surface of cortical bone, trabecular bone, and the blood vessel canals
8

(Volkmann’s canals) present in bone. The endosteum is relatively cellular
containing osteoprogenitor cells, as well blood vessels (Clarke, 2008; Buckwalter
et al, 1995; Buck et al, 2011). Both cortical and trabecular bone contain
specialized cells, organic matrix and mineral phase (Fernandez et al, 2006).
1.2.2 Bone cells
Several cell types can be found in bone (Table 1). Bone cells are located within
the bone tissue itself or in the conjunctive stroma of the bone marrow, which is
rich in mesenchymal stem cells. These cells differentiate into osteoprogenitor
cells that form the osteoblasts and osteocytes, while osteoclasts arise from
hematopoietic stem cells (Buck et al, 2011; Fernandez et al, 2006).

Table 1 Bone cells

Adapted from Buck et al, 2011; Fernandez et al, 2006

Osteoblasts originate from the mesenchymal stem cells of the bone marrow,
endosteum, periosteum, and perivascular pericytes (Canfield et al, 2000).
Osteoblast precursors change shape from spindle-shaped osteoprogenitors to
large cuboidal differentiated osteoblasts on bone matrix surfaces after preosteoblasts stop proliferating. Active mature osteoblasts that synthesize bone
9

matrix have large nuclei, enlarged Golgi structures, and substantial rough
endoplasmic reticulum (Clarke, 2008). Osteoblasts synthesize the organic matrix
or osteoid material at a rate of 2 to 3 μm per day, and express a characteristic
enzyme, alkaline phosphatase (ALP), which orchestrates mineralization at a rate
of 1-2 μm per day. They can also express other osteoblastic markers such as
bone sialoprotein, osteopontin, and osteonectin during the process of
osteoblastic differentiation. It is accepted that they: (i) synthesize the collagen
and non-collagen proteins of the organic bone matrix, (ii) direct the arrangement
of the extracellular matrix fibrils, (iii) contribute to the mineralization of the osteoid
material, due to the alkaline phosphatase, (iv) mediate in the resorption carried
out by the osteoclasts, through the synthesis of specific cytokines, and (v)
synthesize growth factors (Fernandez et al, 2006). Usually after 10 weeks,
osteoblasts can disappear through apoptosis, become transformed into bone
lining cells or into osteocytes (15%) (Aubin and Liu, 1996). Therefore, flattened
bone-lining cells are thought to be quiescent osteoblasts that form the
endosteum on trabecular and endosteal surfaces and underlie the periosteum on
the mineralized surface. Osteoblasts and lining cells are found in close proximity
and

joined

by

adherents

junctions.

Cadherins

are

calcium-dependent

transmembrane proteins that are integral parts of adherent junctions and
together with tight junctions and desmosomes join cells together by linking their
cytoskeletons (Shin, 2000).
Osteoclasts are large multinucleated cells, rich in mitochondria and vacuoles
responsible for bone resorption, located in shallow depressions on bone surfaces
10

called Howship lacunae (Buck et al, 2011; Fernandez et al, 2006; Clarke 2008).
These cells originate from the bone marrow hematopoietic stem cells known as
‘Granulocyte-Macrophage

Colony-Forming

Units’

(GM-CFU),

which

are

precursors of macrophages and monocytes (Fernandez et al, 2005; Compston et
al, 2013). In the process of osteoclastogenesis, marrow stromal cells and
osteoblasts play a critical role since they secrete two essential cytokines:
macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear
factor-kB ligand (RANKL), which is a ligand situated on the surface of the
osteoblasts and pre-osteoblasts (Teitelbaum et al, 2003; Fernandez et al, 2006;
Clarke, 2008; Clifford et al, 2013). RANKL, previously called osteoclast
differentiation factor (Simone et al, 1997), is a transmembrane cytokine
belonging to the tumor necrosis factor family (TNF), and interacts with its
receptor, RANK, expressed by pre-osteoclasts. This interaction initiates
osteoclastic differentiation and activity to promote resorption. M-CSF is required
for the proliferation, survival, and differentiation of osteoclast precursors, as well
as osteoclast survival and cytoskeletal rearrangement required for bone
resorption (Clarke, 2008; Fernandez et al, 2006). In addition, osteoprotegerin
(OPG) is a soluble protein secreted by osteoblasts and pre-osteoblasts that binds
RANKL with high affinity to inhibit its action at the RANK receptor (Cohen, 2006).
When OPG and RANKL bind together, the union between RANK and RANKL is
inhibited, and thus the osteoclastic differentiation is also inhibited. For this reason
OPG, RANK and RANKL are important regulators of osteoclastogenesis
(Fernandez et al, 2006). The other factors and cytokines that regulate osteoclast
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formation and activity, include interleukin-1, interleukin-6, parathyroid hormone,
1,25-dihidroxyvitamin D, and calcitonin (Boyle et al, 2003; Blair and Athanasou,
2004). The membrane of osteoclasts has two special characteristics: a ruffled
border, where resorption takes place, and a clear area rich in microfilaments,
with integrins that serve as an anchor to the matrix. When the resorption process
starts, the osteoclasts move towards the area to be resorbed and then
immediately adhere to the mineralized bone surface with the ruffled border and
sealing the edges of the area with the integrins. The β1 family of integrin
receptors in osteoclasts, particularly αvβ3, recognizes the Arg-Gly-Asp sequence
in the collagen and other proteins of the osteoid matrix. At this level the pH is
acidic since osteoclasts secrete hydrogen ions, generated by carbonic anhydrase
II and proteolytic enzymes such as collagenases, metalloproteases, cathepsin K,
and glucuronidase.These enzymes initiate bone resorption by the solubilization
of, first the organic and, then the mineral matrix. Osteoclasts create a sealing
zone that surrounds and isolates the acidified resorption compartment from the
surrounding bone surface (Ross and Teitelbaum, 1995; Vaananen et al, 2000).
Bone resorption can be blocked by disruption of either the ruffled border or the
actin ring created by the fibrillar actin cytoskeleton of the osteoclast. When the
osteoclasts are actively resorbing, they form podosomes, which attach to bone
matrix, rather than focal adhesions as formed by most cells. Podosomes are
composed of an actin core surrounded by αvβ3 integrins and associated
cytoskeletal proteins (Clarke, 2008).
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Osteocytes represent terminally differentiated osteoblasts and function within
syncytial networks to support bone structure and metabolism. In the adult
skeleton, osteocytes account for 90–95% of all bone cells, compared to 4–6%
osteoblasts and approximately 1–2% osteoclasts (Clarke, 2008; Clifford et al,
2013). Once the matrix is mineralized, some osteoblasts remain trapped within
vacuoles called lacunae, becoming transformed into osteocytes. Osteocytes
maintain connection with each other and cells on the bone surface through
dendritic processes generally radiating towards the bone surface and the blood
supply. The dendritic processes travel through the bone in tiny canals called
canaliculi while the cell body is encased in lacunae. This interconnection allows
osteocytes to function as a network of sensory cells that respond to mechanical
loading through this extensive network (Fernandez et al, 2006; Clarke, 2008;
Clifford et al, 2013). Osteocytes are linked metabolically and electrically through
gap junctions composed primarily of connexin 43 (Plotkin et al, 2002). Connexins
are integral cellular proteins that maintain gap junctions between cells to allow
direct communication through intercellular channels. Gap junctions are required
for osteocyte maturation, activity, and survival (Clarke, 2008).Osteocytes have
long been thought to control biologic activity of bone since they transduce stress
signals from bending or stretching of bone into bone resorption or formation
(Fernandez et al, 2006; Clarke, 2008; Buck and Dumanian, 2011; Clifford et al,
2013).

Signaling

mechanisms

involved

in

mechanotransduction

include

prostaglandin E2, cyclo-oxygenase 2, various kinases, Runx2, and nitrous oxide
(Clarke, 2008). It has also been shown that osteocytes have another important
13

function: to regulate phosphate homeostasis; therefore, the osteocyte network
may also function as an endocrine gland (Clifford et al, 2013). Until recently, the
markers described for osteocytes were limited to low- or no-alkaline
phosphatase, high casein kinase II, high osteocalcin protein expression, and high
CD44 as compared to osteoblasts. At the present time, osteocyte markers such
as E11/gp38, phosphate-regulating neutral endopeptidase on the chromosome X
(Phex), dentin matrix protein 1 (DMP1), sclerostin, FGF23, and ORP150 are well
known (Clifford et al, 2013) (Table 2)

Table 2 Osteocyte markers

Marker
E11/gp38
CD44

Fimbrin
Phex
OF45/MEPE

DMP1
Sclerostin
FGF23
ORP150

Expression
Early embedding cell
More highly expressed in
osteocytes compared to
osteoblasts
All osteocytes
Early and late osteocytes
Late osteoblasts through
osteocytes
Early and mature
osteocytes
Late embedded
osteocyte
Early and mature
osteocytes
Mature osteocytes

Adapted from Clifford et al, 2013
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Function
Dendrite formation
Hyaluronic acid receptor
associated with E11 and
linked to cytoskeleton
Dendritic branching
Phosphate metabolism
Inhibitor of bone
formation/regulator of
phosphate metabolism
Phosphate metabolism
and mineralization
Inhibitor of bone
formation
Induces
hypophosphatemia
Protection from hypoxia

1.2.3 Bone matrix
Bone matrix represents 90% of the composition of the bone volume. It consists of
four major components: inorganic or mineral matrix (65%), organix matrix (20%),
and lipids and water (< 15%) (Clarke, 2008).
Organic matrix, secreted by osteoblasts, is predominantly type I collagen (90%)
(Table 3) with trace amounts of types III and V and FACIT collagens at certain
stages of bone formation that may help define collagen fibril diameter. FACIT
collagens are members of the family of Fibril-Associated Collagens with
Interrupted Triple Helices, a group of non-fibrillar collagens that serve as
molecular bridges that are important for the organization and stability of
extracellular matrices. The presence of small amounts of collagen type III has
been found, related to Sharpey’s fibers. It is believed that collagen has no great
affinity for calcium, for this reason other proteins are involved in mineral
deposition (Fernandez et al, 2006; Clarke, 2008; Buck and Dumanian, 2011).
Osteoblasts also synthesize and secrete non-collagenous proteins which make
up 10 to 15% of total bone protein. The non-collagenous proteins are divided
broadly into several categories, including serum-derived proteins, proteoglycans,
glycosylated proteins, SIBLINGs (Small Integrin-Binding Ligands N-Glycosylated
proteins), gla-containing proteins, and growth factors (Fernandez et al, 2006;
Clarke, 2008; Clifford et al, 2013).
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(i)

Serum-derived

proteins

include,

mainly,

albumin

and

α₂-HS-

glycoprotein. These proteins have good affinity for hydroxyapatite, and
therefore are able to bind to bone matrix.
(ii)

Proteoglycans are large molecules and make up 10% on the noncollagenous proteins, and bone matrix contains several members of
this family such as versican (chondroitin-sulphate), hyaluronan
(glycosaminoglycan),

decorin,

biglycan,

perlecan,

osteoadherin,

lumican, aspirin, and fibromodulin among others.
(iii)

Glycosylated proteins with various functions are abundant in bone.
During bone formation, it is distinctive the synthesis of high levels of
alkaline phosphatase, thus it is considered a good marker of osteoblast
activity. This enzyme liberates inorganic phosphate from phosphoric
esters, and is necessary for mineralization. The most abundant noncollagenous protein produced by bone cells is osteonectin, and it plays
a role in the regulation of cellular adhesion between the matrix and the
cells as well as is important for normal bone mineralization.

(iv)

Bone cells produce at least 12 proteins that may mediate cell
attachment.

Among

them,

they

are

five

proteins

that

are

phosphorylated and/or sulfated, and contain the RGD tripeptide (ArgGly-Asn), also called SIBLINGs: osteopontin, bone sialoprotein, dentin
matrix protein 1 (DMP1), dentin sialophosphoprotein (DSPP), and
matrix extracellular phosphoprotein (MEPE). These glycoproteins are
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essential to bone regeneration and remodeling processes because the
Arg-Gly-Asn sequence is recognized by osteoblast and osteoclast
integrins. They also act as bone cell surface receptors, allowing the
adhesion of the cells to the extracellular matrix, and activating signals.
Other proteins that participate in cell attachment are fibronectin,
vitronectin, fibrillin and thrombospondins.
(v)

Four bone matrix non-collagenous proteins can be distinguished in the
group

of

Gla-containing

proteins:

matrix

gla

protein

(MGP),

osteocalcin, periostin, and protein S. Osteocalcin is a matrix protein
produced by osteoblasts and platelets. In human bone, osteocalcin is
concentrated in osteocytes, and its release may be a signal in the bone
turnover cascade. Its measurements in serum have proved valuable as
a marker of bone turnover in metabolic disease states.
(vi)

Growth factors include the bone morphogenetic proteins, transforming
growth factors β family, interleukin-1, and interleikn-6, for example.
These factors all play important roles in bone osteogenesis,
mineralization, and remodeling (Table 3).
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Table 3 Osteoid matrix
proteins marker

Adapted from Clifford et al, 2013. Primer on the metabolic bone diseases and disorders of
mineral metabolism.
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The inorganic bone matrix accounts for 99% of the body's storage of calcium,
85% of the phosphorous, and 40-60% of the magnesium and sodium stores.
Inorganic matrix is mainly in the form of hydroxyapatite and provides the majority
of bone strength, stiffness, and resistance to compressive forces. Removal of the
inorganic matrix makes bone soft, malleable, and spongy (Buck, 2011). The
extracellular mineralized matrix is now considered as something more than
simply a reservoir of calcium and phosphorous, since it constitutes a reserve of
proteins that participate in the regulation of cellular differentiation and in the
integrity and function of bone tissue (Young, 2003).

1.2.4 Bone growth, modeling, and remodeling
Bone growth occurs longitudinally and radially by the process of endochondral
ossification and appositional bone growth, respectively. Longitudinal growth
occurs at the growth plates, where cartilage proliferates in the epiphyseal and
metaphyseal

areas

of

long

bones,

before

subsequently

undergoing

mineralization to form primary new bone. Appositional bone growth arises at the
level of the periosteum, with subsequent resorption of old bone at the level of the
endosteum (Clarke, 2008; Buck, 2011).
By the process of modeling, the bones change their shape in response to
physiologic influences or mechanical forces. Modeling of the cranium, for
example, is thought to be transmitted via mechano-transduction signals from
underlying brain growth (Stool and Vig, 2003). Bones may enlarge or change
axis by subtraction or addition of bone to the appropriate surfaces by
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independent action of osteoblasts and osteoclasts in response to biomechanical
forces. Bones normally widen with age in response to periosteal apposition of
new bone and endosteal resorption of old bone (Clarke, 2008). Wolff’s law states
that bones change shape to accommodate stresses placed upon them
(Sommerfeldt and Rubin, 2001). In fact, bone resorption occurs if stress does not
happen and is reinforced where stress forces are applied. An example is the
resorption of an edentuolous mandible from the lack of the normal forces of
mastication (Buck, 2011).
Bone remodeling is the process that takes place to maintain bone health and
strength as well as mineral homeostasis. The remodeling process resorbs old
bone and forms new bone to prevent accumulation of bone micro-damage
(Clarke, 2008; Buck, 2011). The bone remodeling unit is composed of a tightly
coupled group of osteoclasts and osteoblasts that sequentially carry out
resorption of old bone and formation of new bone. The remodeling cycle is
composed of four sequential phases; activation, that includes fusion of multiple
mononuclear cells to form multinucleated preosteoclasts; resorption, mediated by
osteoclasts and takes only approximately 2 to 4 weeks during each remodeling
cycle; reversal, where preosteoblasts are recruited to begin new bone formation,
and formation that takes approximately 4 to 6 months to be completed.
Osteoblasts

synthesize

new

collagenous

organic

matrix

and

regulate

mineralization of matrix by releasing small, membrane-bound matrix vesicles that
concentrate calcium and phosphate and enzymatically destroy mineralization
inhibitors

such

as

pyrophosphate

or
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proteoglycans

(Anderson,

2003).

Remodeling begins at birth and continues through adulthood to the time of death
(Clarke, 2008; Buck, 2011).

1.3 Mesenchymal stem cells (MSCs)

1.3.1 History
Although the early work of Tavassoli and Crosby (Tavassoli and Crosby, 1968)
clearly set up proof of an inherent osteogenic potential associated with bone
marrow (BM), the specific identity of any cell functioning as a progenitor of
differentiated bone cells could not be outlined. Few years later, Friedenstein et al
(Friedenstein, 1970), in a series of studies, verified that the ability of bone
marrow cells of generating new bone marrow when transplanted into a different
site, was associated with a secondary subpopulation of BM cells. These cells
were distinct from the majority of hematopoietic cells by their rapid adherence to
tissue culture vessels and by the fibroblast-like appearance of their progeny in
culture, indicating their origin from the stromal compartment of BM (Bianco et al,
2008). These investigators also demonstrated that seeding of BM cell
suspensions at clonal density resulted in the establishment of discrete colonies
initiated by single cells. These colonies represented the colony-forming unit
fibroblastic (CFU-F). Additional study reviews by Friedenstein (Friedenstein,
1990) of in vivo transplantations, led to the conclusion that the progeny a single
BM stromal cell could generate multiple skeletal tissues (bone, cartilage, adipose
tissue, and fibrous tissue). Friedenstein and Owen called this cell a BM stromal
21

stem cell (Owen and Friedenstein, 1988). Consequently, these initial studies
revealed that a second type of stem cell could be present in the BM and,
specifically, in the hematopoiesis-supporting stroma. In 1999, Pittenger et al
(Pittenger et al, 1999) published an additional similar work and the concept of a
non-hematopoietic stem cell in BM start being repeated worldwide. The term
mesenchymal stem cell, proposed previously by Caplan in 1991 (Caplan, 1991)
as an alternative to stromal or osteogenic stem cell, earned wide acceptance.

1.3.2 Biological characteristics of MSCs
Stem cells are defined as clonogenic, undifferentiated cells characterized by their
ability to self-renew and give rise to terminally differentiated cells of multiple
lineages (Shanti et al, 2007; Deng et al, 2008; Eckfeldt et al, 2005). Stem cells
have been isolated and characterized from embryonic, fetal, and adult tissues
(Shanti et al, 2007). Due to ethical, political and technical issues, the use of
embryonic and fetal stem cells is still controversial, so using adult or postnatal
stem cells has become more accepted (Shanti, RM et al, 2007; Deng et al, 2008;
Keller, 2005). A variety of tissues can serve as source for the different type of
adult stem cells (Ratajczak et al, 2014; Sousa et al, 2014; Shanti et al, 2007)
(Table 4).
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Table 4

ADULT STEMM CELLS

The term mesenchymal stem cell is based on the premise that the cells can
differentiate into a variety of mesodermal tissues including bone, cartilage, and
adipose (Si, YL et al, 2011). In line with this concept, an important feature of
MSCs is their ability to differentiate into several mesenchymal lineages such as
osteoblasts, chondrocytes, adipocytes, myoblasts, and tenocytes (Pittenger et al,
1999; Deng et al, 2008; Pittenger, 2008). There is also evidence that MSCs could
have the potential to differentiate into cells of ectodermal lineage such as
neurons, as well as endodermal lineage such as hepatocytes (Jiang et al, 2002;
Lee et al, 2004; Tomita et al, 2007). Moreover, an increasing number of evidence
suggests that MSCs have immunomodulatory properties, anti-inflammatory
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effects, and secrete various growth factors and cytokines (Si, YL et al, 2011;
Shanti et al, 2007; Pittenger, 2008; Chamberlain et al, 2007). The underlying
mechanisms responsible for the immunosuppressive and anti-inflammatory
effects of MSCs are not completely understood yet (Si et al, 2011; Shanti et al,
2007). Nonetheless, evidence states that MSCs lack immunogenicity based on
their immune phenotype. They express low levels of major histocompatibility
complex-I (MHC-I), do not express MHC-II or costimulatory molecules that
include CD40, CD80, and CD86 (Le Blanc and Ringden, 2007; Tse et al, 2003).
Consequently, MSCs will not activate allogeneic or xenogeneic lymphocytes (Si
et al, 2011). In addition, MSCs are able to suppress the activation and
proliferation of both T and B lymphocytes (Jones et al, 2007; Corcione et al,
2006). MSCs secrete growth factors and cytokines which exhibit autocrine and
paracrine activities (Pittenger, 2008) that may modulate inflammation, apoptosis,
fibrosis of damaged tissues and tissue regeneration (Si et al, 2011). Some of
these include vascular endothelial growth factor (VEGF), stem cell factor (SCF1), macrophage colony stimulating factor (M-CSF) and interleukins (IL-1, -6, -7, 8, -11, -14, and -15), stromal cell-derived factor (SDF-1) (Haynesworth et al,
1996; Reese et al, 1999; Pittenger, 2008). There are still no uniformly accepted
markers to confirm homogeneity of MSCs (Si et al, 2011; Shanti et al, 2007;
Chamberlain et al, 2007; Chen and Tuan, 2008). For this reason, the
International Society for Cell Therapy has issued the minimal set of standard
criteria to identify MSCs (Dominici et al, 2006). These include: (i) the ability to
adhere to plastic surfaces under standard culture conditions; (ii) positive
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expression of CD73, CD90, and CD105; (iii) lack of expression of CD14, CD19,
CD 31, CD34, CD45, and human leucocyte antigen-DR (HLA-DR) surface
molecules; (iv) multipotent ability to differentiate into bone, cartilage, and adipose
tissue; and (v) immunomodulatory functions.
In addition to the bone marrow, MSCs are also found in almost all postnatal
organs and tissues, including periosteum, adipose tissue, periodontal ligament,
dermis, deciduous teeth, vascular pericytes, trabecular bone, umbilical cord and
umbilical cord blood as well as amniotic membrane (Bianco, 2008; Rebelatto et
al, 2008; Seo et al, 2004; Miura et al, 2003; Markov et al, 2007; Brighton et al,
1992; Mageed et al, 2007; Alviano et al, 2007; Si et al, 2011). Bone marrow,
adipose tissue, umbilical cord blood, and umbilical cord are usually considered
as the main sources of MSCs for tissue regeneration and engineering (Si et al,
2011). Apart from being the first documented source of MSCs, bone marrow has
proven to be reproducible and convenient site in all species for harvesting MSCs.
(Si et al, 2011; Pittenger, 2008). While MSCs from different tissues display
similar basic biological features, there are considerable disparities among them
such as difference in the expansion potential under identical culture conditions
(Kern et al, 2006), and age-related functional properties. Furthermore, the
existence of site-specific variation in bone cell responses has been suggested in
the literature. Diverse studies have proposed that MSCs derived from craniofacial
and axial/appendicular bones are phenotypically and functionally distinctive
based on their different embryological origins (Akintoye et al, 2006; Gronthos et
al, 2006). The jaw bones arise embryologically from neural crest cells of the
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neuroectoderm germ layer, while the axial and appendicular bones arise from the
mesoderm (Akintoye et al, 2006; Aghaloo et al, 2010; Chai and Maxson, 2006).
In addition, the mandible and maxilla, are formed by intra membranous
ossification and, in the case of the mandible, secondary cartilage at its proximal
end contributes endochondral components at later stages of development.
Meckel's cartilage participates, to a limited extent, in the formation of the
mandible, but two secondary cartilages (coronoid and condylar) contribute also to
the mandible (Clifford et al, 2013). Furthermore, the jaw bone could develop nonodontogenic bone pathologies such as osteoclast-like giant cells and fibrous
lesions found in cherubism (Ueki et al, 2001) and hyperparathyroid jaw tumor
syndrome that do not occur in non-oral bones (Simonds et al, 2002). Additionally,
osteonecrosis

of

the

jaws

caused

by

bone

antiresorptives

such

as

bisphosphonates and denosumab (Ruggiero et al, 2004) affect only the maxilla
and mandible, suggesting different homeostatic mechanisms between the jaws
and long bones. In an earlier study on skeletal site-dependent responsiveness of
bone cells, Malpe et al (Malpe et al, 1997) assessed their responsiveness to
insulin-like growth factors (IGFs), which are important regulators of bone
metabolism. They concluded that there are skeletal site-dependent differences in
the production of IGF system components and suggest that the regulation of
bone metabolism may vary at various skeletal sites.
Akintoye et al (Akintoye et al, 2006) investigated skeletal site-specific phenotypic
and functional differences between orofacial (maxilla and mandible) and axial
(iliac crest) human BMSCs in same individuals in vitro and in vivo. The results
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suggested that orofacial BMSCs are unique cell populations, and that the
differences between both types of cells are skeletal site-dependent, possibly
related to distinctive embryological origins and adjustment to functional demands
at each skeletal site.
Aghaloo et al (Aghaloo et al, 2010) hypothesized that rat mandible vs. long-bone
marrow-derived cells possess different osteogenic potential. By using bone
marrow stromal cells derived from rat mandible and from rat tibiae, these
investigators compared the in vitro osteoblastic differentiation and in vivo bone
formation capacity of both cell types. They reported that there is an amplified
osteogenic potential and augmented capacity of mandibular BMSCs to induce
bone formation in vitro and in vivo.

1.3.3 Clinical applications of MSCs
MSCs are viable cell populations for tissue engineering, regenerative medicine,
and autoimmune disease therapy because of their multipotent capacity, ease of
culture expansion and low immunogenicity (Chamberlain et al, 2007; Meirelles et
al, 2008; Si et al, 2011).
a) MSCs in cardiovascular conditions
Some studies have demonstrated that MSCs could have an important function in
myocardial infarctions and ischemic cardiomyopathies (Psaltis et al, 2008;
Ohnishi et al, 2007). This therapeutic capacity could be completed by different
functions such as direct differentiation into cardiac tissue (Gojo et al, 2003);
secretion of cytokines and growth factors (Kinnaird et al, 2004); through
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immunosuppressive properties that might decrease inflammation of damaged
myocardial tissue (Du et al, 2008); and through stimulation of endogenous repair
(Paul et al, 2009). In the study by Gojo et al

(Gojo et al, 2003), it was

demonstrated that the injection of adult MSCs into healthy adult myocardium
could produce cardiomyocytes, endothelial cells, and pericytes or smooth muscle
cells, revealing that cultured MSCs have the capacity to engraft into healthy
tissue and can differentiate into several cell types in vivo.
a) MSCs in diabetes
Therapeutic efficacy of MSCs in diabetes mellitus has been mentioned in some
reports. In the study by Chao et al (Chao et al, 2008), for example, MSCs from
Wharton’s jelly of the human umbilical cord were successfully differentiated into
mature islet-like cell clusters with the ability of producing insulin in vitro and in
vivo. Working with mice, Ezquer et al (Ezquer et al, 2008) demonstrated that the
systemic

administration

of

bone

marrow-derived

MSCs

could

control

hyperglycemia and prevents renal damage in type I diabetes. Nonetheless, the
mechanisms by the MSCs could have this therapeutic effect is still unclear. Some
authors (Xie et al, 2009) have proposed that MSCs differentiate directly into
functionally competent new β-cells.
b) MSCs in neurological disorders
According to some studies, MSCs could have neuroprotective effects in central
nervous system injuries and progressive degenerative diseases. This role has
been described for spinal cord injuries (Himes et al, 2006); Parkinson’s disease
(Park et al, 2008); autoimmune encephalomyelitis (Zhang et al, 2006), and
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multiple system atrophy (Lee and Park, 2009), among others. Interestingly, it is
unrevealed if MSCs could differentiate into neural cells in vivo. Blandini et al
(Blandini et al, 2010) showed that human MSCs in vitro expressed some neural
markers including nestin, β III tubulin and

microtubule-associated protein 2

(MAP-2), but did not express a glial or specific neuronal markers. However, after
these cells were transplanted into rats, they lost positivity for nestin and
expressed a glial-like phenotype. Hofstetter et al (Hofstetter et al, 2002) found
that rat MSCs injected into rats with spinal cord injuries, formed guiding strands
in the injured spinal cord facilitating regeneration.
c) MSCs in graft-versus-host disease (GVHD)
As a result of the immunomodulatory properties of MSCs, infusions of this cell
type have been used to treat GVHD developed in patients with allogeneic
hematopoietic stem cell transplantations (Si et al, 2011). Le Blanc et al (Le Blanc
et al, 2004) transplanted haploidentical mesenchymal stem cells in a patient who
had progressive severe GVHD that was unresponsive to all types of therapy.
They reported remarkable decrease of symptoms in this patient. Later, in a
multicenter, phase II experimental study, Le Blanc et al (Le Blanc et al, 2008)
treated 55 patients with steroid-resistant, severe, acute GVHD with mesenchymal
stem cells. More than 50% of the patients had a complete response and nine
showed improvement.
d) MSCs in bone/cartilage defects
Degenerative bone diseases such as osteoarthritis (OA), rheumatoid arthritis
(RA), and osteogenesis imperfecta (OI) have found great treatment options in
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MSCs. Properties of MSCs such as the ease of isolation and expansion and the
multipotential differentiation capacity, especially the chondrogenic differentiation
property of MSCs, make MSCs the cell type of choice for articular cartilage tissue
engineering that intends to replace and regenerate the diseased structure in joint
diseases. Moreover, their potent immunosuppressive and anti-inflammatory
functions can be harnessed for therapeutic application in degenerative joint
diseases mentioned above (Chen and Tuan, 2008). Cartilage tissue engineering
has used the chondrogenic differentiation potential of MSCs loaded on a three
dimensional (3-D) scaffold as replacement tissue for cartilage repair (Chen and
Tuan, 2008). In addition, MSCs have been used directly in cell therapy for in situ
repair of OA cartilage. The study performed by Murphy et al (Murphy et al, 2003),
treated induced OA in goats with autologous MSCs in hyaluronan solution. Their
results demonstrated inefficient engraftment of MSCs to articular cartilage. They
concluded that the favorable effect of MSCs, on cartilage protection and on OA
progression, was probably due to induction of endogenous progenitor cells.
These cells were responsible to regenerate meniscus that, in turn, retarded
cartilage degeneration associated with OA. This study, and others (Augello et al,
2007; Noth et al, 2008), have suggested that MSC-based graft exert a
therapeutic effect in arthritis, possibly through their trophic effect and their antiinflammatory and immunosuppressive actions, which can significantly affect the
local environment and resident endogenous tissue progenitor cells in carrying out
the regenerative function (Chen and Tuan, 2008). A T-cell-mediated systemic
disease like RA is characterized by articular cartilage damage (Si et al, 2011),
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and the potential therapeutic value of MSCs in its treatment has been evaluated
in some studies. Zheng et al (Zheng et al, 2008) showed that bone marrowderived MSCs and MSC-differentiated chondrocytes could suppress type II
collagen-reactive T-cell responses in RA. This suggests that MSCs could be a
potential candidate for RA treatment in future if this is further confirmed in vivo.
Horwitz et al (Horwitz et al, 2002) demonstrated the viability of bone marrowderived mesenchymal cells therapy in a group of six children with severe OI.
They infused allogeneic cells and five patients showed engraftment in one or
more sites, including bone, skin, and marrow stroma, and had an acceleration of
growth velocity during the first 6 months post-infusion. Despite the outcomes of
all studies mentioned above, caution should be exercised as this field of research
is still developing and conflicting results have been reported in different systems
from different labs (Chen and Tuan, 2008; Si et al, 2011).
e) Applications in maxillofacial surgery
MSCs have shown to be an ideal cell source for maxillofacial tissue engineering.
When these cells are used with scaffolding materials that possess suitable
biological and physical properties, tissue regeneration from cell-based therapies
can produce desirable clinical outcomes (Shanti et al, 2007). MSCs have been
also used to deliver genes or gene products such as bone morphogenetic
proteins for bone repair (Chang et al, 2003) or the use of bone marrow-derived
MSCs as vehicles for chemotherapeutics (e.g. Interferon-β) into tumors (Studeny
et al, 2002). A number of delivery vehicles loaded with MSCs have been
employed to heal critical-sized segmental bone defects. An example of this is the
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study by Bruder et al (Bruder et al, 1998) who examined the effect of cultured
autologous MSCs on the healing of critical-sized segmental defects in the femora
of adult female dogs. The cells were loaded onto porous ceramic of
hydroxyapatite and beta-tricalcium phosphate ceramic. It was found a greater
amount of bone in the implants that had been loaded with mesenchymal stem
cells compared with the implants that had not been loaded with cells. In pediatric
patients, cell-based tissue engineering, preferably using autologous cells,
presents a promising, alternative method for skull bone reconstruction (Shanti et
al, 2007). A 7-year-old girl with widespread calvarial defects after severe head
injury was successfully treated with autologous adipose-derived stem cells that
were grafted to the calvarial defects (Lendeckel et al, 2004). The stem cells were
kept in place using autologous fibrin glue. Mechanical fixation was attained by
two large, resorbable macroporous sheets acting as a soft tissue barrier at the
same time. After 3 months, postoperative computed tomography scans showed
new bone formation and near complete calvarial continuity. Certainly, more
advances in the engineering of craniofacial bone are necessary, as well as
development of resorbable scaffolds that will replicate tissue shape and form
while degrading in a controlled manner (Shanti et al, 2007). Another maxillofacial
use of MSCs is in temporomandibular joint (TMJ) reconstruction. As the TMJ is
susceptible to diverse degenerative pathologies, cell-based tissue engineering
approaches using MSCs for the replacement of mandibular condyles offer an
important therapeutic option (Shanti et al, 2007). In the literature some reports
(Alhadlaq et al, 2003; Tuli et al, 2004) have described different approaches for
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the ex vivo development of articular tissue component, such as mandibular
condyle. However, a significant amount of research is still needed before tissueengineered mandibular condyles can be placed for clinical uses (Shanti et al,
2007).

1.3.4 Isolation of MSCs
MSCs can be obtained from multiple tissues but bone marrow offers the most
readily available source. Most of the information about MSCs, specifically
biological properties and characteristics, is from bone marrow-derived cells
(Shanti et al, 2007). In vitro MSCs expansion is necessary for regenerative and
immunotherapeutic approaches since

adult bone marrow contains low

percentage of MSCs and a significant number of cells is required for the
specialized therapies (Sotiropoulou et al , 2006). Effective isolation and
expansion of MSCs depends on several factors such as culture medium, starting
and passaging cell-plating density, culture surfaces, addition of supplementary
factors, and the effects of donor age and cryopreservation (Colter et al, 2000;
Sekiya et al, 2002; Caterson et al, 2002; Pittenger, 2008; Sotiropoulou et al ,
2006). Many different formulations of growth media have been used in
experimental and clinical protocols to isolate and growth MSCs (Pittenger, 2008;
Sotiropoulou et al, 2006).
Numerous methods have been proposed for qualitative assessment of MSCs
isolated for clinical use varying from simple colony-forming assays to more
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complex morphological characterizations. To mention some of these approaches,
in the study by DiGirolamo et al (DiGirolamo et al, 1999) the replicative potential
of human marrow stromal cells was evaluated by a simple colony-forming assay
in which samples from early passages were plated at low densities of about 10
cells per cm2. On the other hand, Smith et al (Smith et al, 2004) proposed a more
sophisticated morphological analysis that may be useful as a rapid method to
characterize small stem-like cells from a number of adult tissues. Sotiropoulou et
al (Sotiropoulou et al, 2006) investigated the optimal culture conditions for
isolation and expansion of human MSCs. Among several growth media, they
concluded that those based on α-Minimum Essential Medium (α-MEM) are more
suitable for both isolation and expansion of multipotent MSCs. In cell culture
processes, the addition of L-glutamine to the medium has been considered a
problem, as reported in some studies. This compound is susceptible to both
chemical and metabolic deamination, producing ammonia which can be inhibitory
to cell growth. Therefore, glutamine-containing dipeptides such as alanylglutamine and glycyl-glutamine have been considered as potential substitutes for
glutamine in culture medium due to their stability (Christie and Buttler, 1994;
Sotiropoulou et al, 2006). The other major component of MSCs isolation and
growth media is fetal bovine serum (FBS). Most media preparations usually use
10% fetal calf serum to provide a mixture of undefined growth factors, cytokines,
and attachment factors.

FBS contains, particularly, platelet-derived growth

factor (PDGF), basic fibroblast growth factor (b-FGF or FGF-2), and epidermal
growth factor (EGF) as well as small amounts of other growth factors. It has been
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established that serum-free defined media lack attachment factors to aid MSC
attachment and cell yields tend to be low (Pittenger, 2008). Regarding passaging
cell-plating density, Sotiropoulou et al (Sotiropoulou et al, 2006) found that initial
plating densities of 5,000 to 10,000 cells/cm 2 resulted in much higher numbers of
the starting MSC-enriched adherent population. These results are consistent with
previous reports that have evaluated parameters for MSCs expansion and
displayed that plating MSCs at low density benefits proliferation and stemness
preservation (Sekiya et al, 2002; Colter et al, 2001; Prockop et al, 2001).
Sotiropoulou et al (Sotiropoulou et al, 2006) also stated that an additional factor
that influences the expansion of human MSCs is the quality of plastic surface
used for their adhesion. These investigators used culture flasks from four
different companies and demonstrated that the quality of cells produced did not
differ among the different types of flasks. In addition, this study assessed effect
of b-FGF concentrations on MSCs proliferative capacities. This study supports
previous reports (Tsutsumi et al, 2001; Hori et al, 2004) that isolation and
proliferative potential of MSCs are dose-dependent.

1.3.5 MSCs model organisms
MSCs have important applications not only in human regenerative medicine but
also in veterinary medicine. Animal models are widely used to study the
properties and potential of stem cells providing valuable information for future
applications in human medicine (Ribitsch et al, 2010). Currently, the focus of
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attention in veterinary medicine and research is the use of MSCs from either
extra embryonic or adult tissues.
Most of the conventional MSC research has been performed by using cells
isolated from humans and murine models. Nonetheless, MSCs have also been
isolated from unconventional model organisms, such as cat (Felis catus), dog
(Canis familiaris), chicken (Gallus gallus), duck (Anas platyrhyncha), goat (Capra
hircus), buffalo (Bubalus bubalis), cattle (Bos taurus), rabbit (Oryctolagus
cuniculus), pig (Sus scrofa), sheep (Ovis aries), horse (Equus caballus) and
guinea pig (Cavia porcellus) (Calloni et al, 2014).
a) Cat (Felis catus)
Martin et al (Martin et al, 2002) isolated, for the first time, feline MSCs from bone
marrow. Later, other reports have described isolation of MSCs from adipose
tissue (Webb et al, 2011), umbilical cord blood (Jin et al, 2008), and fetal fluid
and membranes (Iacono et al, 2012). Cat MSCs exhibit a morphology similar to
MSCs isolated from mice and humans, characterized by the expression of classic
MSC-associated markers (CD9, CD44, CD90 and CD105) and the absence of
the surface proteins CD14, CD34 and CD45 (Calloni et al, 2014).
b) Cattle (Bos Taurus)
Studies have reported isolation of bovine MSCs from bone marrow and umbilical
cord (Bosnakovski et al, 2005; Mauck et al, 2006). They express the cell surface
markers CD29, CD73, CD90 and CD105 and present a fibroblast-like
morphology. Generally, most of these bovine MSCs studies have investigated in
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vitro culture systems to achieve and analyze chondrogenic differentiation (Calloni
et al, 2014).
c) Rabbit (Oryctolagus curriculus)
Different tissues have served as a source of rabbit MSCs: bone marrow, adipose
tissue, peripheral blood, synovium, periosteum, placenta and fetal liver (Moreno
et al, 2010; Hui et al, 2005; Lee et al, 2012). Morphology of the cells resembles
the classic fibroblast-liike shape and can differentiate in vitro into chondroblasts
and epithelial-like cells (Li et al, 2012: Wan et al, 2006). Other reports have
demonstrated in vivo and in vitro differentiation to osteoblasts, adipocytes and
corneal epithelial cells (Wan et al, 2006; Gu et al, 2009).
d) Sheep (Ovis aries)
Ovine MSCs have been isolated from bone marrow, particularly from the iliac
crest region, adipose tissue, amniotic fluid, dental pulp and periodontal ligament
(Niemeyer et al, 2010; Martinez-Lorenzo et al, 2009; Shaw et al, 2011). However,
in 2003 MSCs were isolated for the first time from sheep umbilical cord (Murphy
et al, 2003). Rentsch et al (Rentsch et al, 2010) reported that ovine MSCs and
human-derived MSCs have similar proliferative characteristics and differentiated
into the same lineages. Other studies have reported specifically in vitro and in
vivo adipogenic and osteogenic differentiation (Niemeyer et al, 2010; Rentsch et
al, 2010).
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1.4 Canine mesenchymal stem cells (cMSCs)

1.4.1 Why characterize cMSCs?
To optimize clinical applications of stem cells, it is paramount to test safety and
efficacy in large-animal models of preclinical studies. Canine models are known
to accurately predict clinical outcomes in adult stem cell transplantation and are,
therefore, likely to act as accurate preclinical models for stem cell therapies. In
fact, long-term outcomes of organ or hematopoietic transplantation in dogs have
accurately predicted outcomes in humans (Csaki et al, 2007; Hayes et al, 2008;
Volk et al, 2012)
Using dogs as dependable preclinical models in the development of cellular
transplantation therapies has important advantages over some other laboratory
animals. Canines experience external and environmental elements that are
associated with different pathologies such as cancer, obesity, and traumatic
injuries. Also the clinical presentation and progression of these diseases are
similar to their equivalents in humans (Parker et al, 2010; Volk et al, 2012).
Distinctive treatment options, imaging, and repeated biological sampling are,
especially, possible in dogs due to their size and availability of vital veterinary
infrastructure. These circumstances plus continuing clinical progresses in
companion animal care have increased sensitivity to detect adverse side effects
of new therapies that would otherwise reduce risks to humans (Volk et al, 2012).
Clearly, canine model has a significant value for translational studies that can
advance human medicine and also enhance veterinary therapies. For further
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advancements of cMSC-based regenerative medicine and tissue engineering, it
is essential to gain more insight into their differentiation capacity, define donor
characteristics, refine ex vivo expansion strategies, and evaluate the tissues
formed

by

these

cells

at

the

biochemical,

ultrastructural

and

immunomorphological levels.

1.4.2 What is known about cMSCs?
Canine mesenchymal stem cells (cMSCs) can be obtained from numerous
sources such as bone marrow, adipose tissue, umbilical cord blood, umbilical
cord matrix, umbilical cord vein, periodontal ligament, dental pulp, amniotic fluid,
and amniotic membrane (Vieira et al, 2010; Reich et al, 2012; Volk et al, 2005;
Volk et al, 2012; Dissanayaka et al, 2011; Wang et al, 2012; Seo et al, 2009;
Zucconi et al, 2010; Uranio et al, 2011; Kisiel et al, 2012). The greatest volume of
the studies on cMSCs has been performed using cells from bone marrow and
adipose tissue. The procedure for obtaining bone marrow in dogs is usually easy
and relatively non-invasive. Commonly used donor sites are the proximal
humerus, proximal femur or the tuber coxae (Crovace et al, 2008; Fortier and
Travis, 2011). Adipose tissue is also considered an attractive source for MSCs,
mainly, due to the accessibility of the tissue at various sites in the body (Stewart
& Stewart, 2011), and ability to collect it during routine canine surgery or
liposuction techniques (Vieira et al, 2010). Depending on the source from which
the cells are isolated, canine MSCs can be passaged around 6 to 11 times
(Martinello et al, 2011). In the literature, there are various reports that have
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reported about characterization of cMSCs based on their morphology,
immunophenotype, and gene expression (Table 5).
Table 5

Adapted from de Bakker et al, 2014. Veterinary Quarterly, 2014

Morphologically the cMSCs display the typical fibroblast-like shape, but with
some variations such as elongated and cuboidal outlines (Csaki et al, 2007; De
Schauwer et al, 2011). Depending on the source of the cells, several studies
have showed that cMSCs have a variable surface marker profile. These reports
showed positive and simultaneous expression of several markers such as CD29,
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CD44, CD90, and MHC-I, while being negative for CD34, CD45, CD14, CD105,
and MHC-II, among others (Table 5).
Mathieu et al (Mathieu et al, 2009) emphasized the importance of using specific
anti-canine antibodies in cell surface marker characterization due to the lack of
cross-reactivity between the dog cell surface markers and human antibodies.
This fact could explain some negative results for classic MSCs markers in canine
cells. Interestingly, some trials have demonstrated that cMSCs secrete various
cytokines that allow them to inhibit leucocyte proliferation. Kang et al (Kang et al,
2008) demonstrated that canine adipose-derived MSCs expressed soluble
factors such as transforming growth factor beta, IL-6, IL-8, vascular endothelial
growth factor, hepatocyte growth factor, and others. These factors were
associated with immunomodulatory effects of the cMSCs. As human MSCs,
cMSCs also express pluripotency-associated transcription factors NanoG, Oct4,
and Sox2 (Table 5).
Generally,

one

chondrogenic,

important
and

characteristic

adipogenic

potential

of

MSCs

is

their

(Pittenger

et

al,

osteogenic,
1999).

This

differentiation capacity has also been demonstrated in cMSCs isolated from bone
marrow and adipose tissue. In addition, some authors have investigated cMSCs
harvested from other anatomical parts such as amniotic membrane, umbilical
cord blood, Wharton’s jelly, muscle, periosteum (Csaki et al, 2007; Neupane et
al, 2008; Vieira et al, 2010; Volk et al, 2012; Kisiel et al, 2012; Park et al, 2012;
Kang et al, 2012; Guercio et al, 2013)

41

Volk et al (Volk et al, 2012) studied canine bone marrow-derived MSCs obtained
from humerus, femur, tibia, an iliac crest and the effects of donor characteristics
(age and harvest site) and ex vivo expansion on the differentiation potential of
the cells. Osteogenesis, chondrogenesis, and adipogenesis were, particularly,
evaluated. The authors found that advancing age had a negative effect on
colony-forming unit-fibroblastic as well as osteogenic potential. Site of harvest
was also found to have substantial effects on MSC properties.
Csaki et al (Csaki et al, 2007) verified the in vitro multilineage differentiation
potential of isolated adult canine bone marrow MSCs from femur, at the
ultrastructural and immunomorphological levels. They demonstrated that the cells
had proliferative capacities and, under appropriate culture conditions could
differentiate well into functional osteoblasts, adipocytes and chondrocytes during
in vitro development.
Park et al (Park et al, 2012) isolated and characterized MSCs from six different
canine amniotic membrane tissues. They demonstrated that the amniotic
membrane-derived MSCs proliferated actively, showed adherence to plastic
culture surface and their morphology was similar to those typical MSCs with a
spindle, fibroblast-like shape. Additionally, the cells displayed multipotent
differentiation capacity of osteogenesis, adipogenesis, neurogenesis, and
chondrogenesis in vitro.
Kisiel et al (Kisiel et al, 2012) firstly, isolated and characterized canine musclederived MSCs and periosteum-derived MSCs. Secondly; they compared the
proliferation potential of MSCs from these two potential donor sites with two
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conventional canine sources; bone marrow and adipose tissue. These
investigators were able to demonstrate that plastic-adherent cells, with the
distinctive fibroblastic phenotype, were isolated and expanded from all four donor
tissues. Furthermore, the cells expressed surface markers CD90 and CD44, and
were negative for CD34 and CD45. Positive expression of pluripotencyassociated transcription factors Sox2, Oct4, and NANOG was also noticed. In
terms of differentiation ability, muscle-derived MSCs appeared to have the
greatest adipogenic potential compared with the other tissue-derived MSCs.
Osteogenic differentiation was achieved in all four MSC types demonstrated by
the expression of alkaline phosphatase, Runx2, osterix, and osteopontin,
however the study does not indicate the tissue that exhibited higher or lower
expression of these bone markers.
The authors reported that their attempts at differentiating canine MSCs into the
chondrogenic

lineage

were

unsuccessful

based

on

morphological

and

histochemical assessments. Periosteum was a superior tissue source in
providing the greatest number of MSCs per gram of tissue when the cells were
grown to 80% to 100% confluence in passage 1, suggesting that periosteum
derived cMSCs may be useful in allogeneic applications.
Osteogenic differentiation has been demonstrated by morphological changes of
the cells under induction, which have adopted polygonal appearance containing
nodular aggregates that stained positively with von Kossa. Ultrastructural cellular
changes, translated into a bigger number of cell organelles, and a well-organized
extracellular matrix have been observed through transmission electron
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microscopy. Additionally, cultures grown under osteogenic conditions have
deposited a mineralized matrix that has stained with Alzarin red S. To
complement mineralization assays, mRNA levels or protein expression of
osteogenic markers such as Runx2, collagen type I, bone sialoprotein,
osteonectin, osterix, osteopontin, and osteocalcin have been assessed (Kadiyala
et al, 1997; Csaki et al, 2007; Neupane et al, 2008; Vieira et al, 2010; Volk et al,
2012).
Adipogenic differentiation has been confirmed by the presence of round- shape
cells with cytoplasmic lipid vacuoles stained with Oil Red O technique. Under
electron microscopy the newly formed adipocytes have confirmed the
accumulation of lipid droplets in their cytoplasm with well-developed rough
endoplasmic reticulum and mitochondria. Characterization of the adipogenic
extracellular matrix by immune-electron microscopy has revealed abundant
amounts of collagen type I and adiponectin, the most abundant protein in
adipose tissue. Based on real-time PCR and Western blotting, cells under
adipogenesis induction have displayed significant amounts of adiponectin,
upregulation

of

the

adipocyte-specific

transcription

factor

peroxisome

proliferative-activated receptor γ (PPARγ), lipoprotein lipase (LPL), fatty acid
binding protein-4 (FABP4), and β1-integrin. PPARγ is important for adipocyte
differentiation and stabilizing the metabolic function of differentiated adipocytes
(Lazar et al, 2002; Csaki et al, 2007; Neupane et al, 2008; Vieira et al, 2010; Volk
et al, 2012)
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Chondrogenic differentiation has been characterized by the accumulation of
glycosaminoglycans (GAG) evidenced by Alcian blue staining in the differentiated
cMSCs. Analysis through transmission electron microscopy has shown newly
formed chondrocytes with round shape, and containing high amounts of
glycogen, numerous cell organelles, and augmented quantities of euchromatin in
nuclei. Immuno-transmission electron microscopy has disclosed that newly
formed extracellular matrix contained abundant amount of collagen type II and
cartilage specific proteoglycans (CSPG). Western blot analysis of whole cell
extracts have confirmed high amounts of collagen type II, CSPG, and activation
of the cartilage specific transcription factor sex-determining region Y box 9
(Sox9) (Csaki et al, 2007; Neupane et al, 2008; Vieira et al, 2010; Volk et al,
2012).
As illustrated above, osteogenic, adipogenic, and chondrogenic differentiation
have been mostly reported for cMSCs. Nonetheless, the potentials of these cells
to differentiate into other lineages such as myogenic (Vieira et al, 2010;
Martinello et al, 2011) or neurogenic lines (Kamishina et al, 2006; Seo et al,
2009; Park et al, 2012; Oda et al, 2013) have also been documented.
Vieira et al (Vieira et al, 2010) reported isolation, characterization, and
multilineage differentiation potential of canine adipose-derived MSCs, obtained
from subcutaneous adipose tissue by liposuction and biopsy procedures.
Besides demonstrating the cMSCs were able to differentiate into adipogenic,
chondrogenic, and osteogenic cells, they also showed differentiation ability into
myogenic lineage. After 10 days in myogenic medium, adipose-derived MSCs
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formed multinucleated structures. Myogenic differentiation was confirmed by the
expression of myosin measured through immunofluorescence, and gene
expression levels of myogenin, dystrophin, and MyoD only in induced cells.
Oda et al (Oda et al, 2013) used three previously reported methods to
differentiate cMSCs, harvested from iliac crest, into neuron-like cells. Then, the
cells were characterized according to morphological analysis and expression of
neuronal markers. cMSCs under neurogenic induction experienced sequential
changes in their appearance, from fibroblastic to neuron-like cells with multiple
branching processes. Immunocytochemical analysis showed that the induced
cells expressed markers of both immature neurons (nestin, 84.7%) and mature
neuronal cells (microtubule-associated protein-2 (MAP2), 95.7%; βIII-tubulin
protein, 12.9%; glial fibrillary acidic protein (GFAP), 9.2%). The investigators
concluded that, under appropriate in vitro conditions, canine bone marrowderived MSCs can be efficiently differentiated into cells with neuronal
phenotypes.
In the study by Park et al (Park et al, 2012), neurogenesis differentiation was
evaluated using amniotic membrane-derived canine MSCs. The authors
measured the expression of the neural-associated markers GFAP, βIII-tubulin,
and MAP2 by immunostaining and real-time PCR. Induced cMSCs expressed
GFAP assessed at both protein and gene levels and in non-induced cells. The
specific neural markers βIII-tubulin and MAP2 were expressed in cells cultured
under neural differentiation conditions.
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1.4.3 What is unknown about cMSCs?
Full understanding of cMSCs biology is yet to be conclusively elucidated. More
detailed knowledge of differentiation and manipulation of cMSCs into other
tissues are crucial to their application for MSC-based therapies in veterinary
medicine, and indirectly in human MSC-based therapies.
Few studies have been published targeting certain factors that may have
significant effects on differentiation capacity and culture expansion of cMSCs.
Precise definition of optimal donor age may have significant impact when
decisions have to be made on choice of autologous or allogeneic MSC therapies.
If autologous cells are to be used for clinical trials in older individuals, it is very
important to determine if the age of the donor will influence the outcomes of the
therapy (Volk et al, 2012). MSC-based therapies require a significant number of
cells; therefore, the knowledge of ex vivo cell expansion, and associated
variables should be completely clarified. Volk et al (Volk et al, 2012) studied the
influence of cell passage on the osteogenic capacity of cMSCs, and found that
this diminishes with increasing passage. The authors suggested that the
shortening of MSC telomere length may explain this diminished differentiation
capacity. Beside culture expansion, it is important to also assess post-expansion
cell yield per gram of donor tissue and specific characteristics of induction media
used for cMSCs culture (Volk et al, 2012; Kisiel et al, 2012; de Bakkler et al,
2014).
As previously stated, a number of studies have reported isolation and in vitro
differentiation capacity of cMSCS, but not many trials have followed up to identify
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their cell surface markers and mRNA expression profiles. Furthermore, the
mechanisms by which cMSCs act to repair individual tissues in vivo are still
unclear. More preclinical or clinical studies are necessary to define if the cMSCs
function through direct differentiation into specific tissue lines, immunomodulatory
action and secretion of growth factors, or both.
Skeletal site-specific properties of cMSCs from the same subject and their sitedependent effects on tissue regeneration have not been clearly defined. Previous
studies focusing on bone marrow-derived as well as adipose-derived cMSCs
suggest that MSC frequency and differentiation capacity may also be influenced
by the specific site of tissue harvest, but these studies have compared response
of MSCs from long bones, with the absence, to our knowledge, of trials making
comparisons between cells from the orofacial region and axial/appendicular
skeleton ((Csaki et al, 2007; Neupane et al, 2008; Vieira et al, 2010; Kisiel et al,
2012; Volk et al, 2012).
Although many of the tendon/ligament injuries present in humans are also
frequently diagnosed in dogs (de Bakker et al, 2013), regenerative MSC-based
therapies for this kind of lesions, either traumatic or degenerative, have not been
completely investigated in canine medicine (de Bakker et al, 2014).

1.4.4 Therapeutic applications of cMSCs
The use of MSCs as an alternative treatment option for several canine diseases
such as spinal cord injuries, bone defects/ degenerative diseases, cardiovascular
pathologies, metabolic diseases, and others has been reported in the literature.
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Trials on healing of spinal cord injury have found cMSCs to be sustainable
therapies. Jung et al (Jung et al, 2009) determined the efficacy of autologous and
allogeneic bone marrow-derived MSC transplantation in experimentally-induced
spinal cord injury of dogs. By using three groups of 10 beagle dogs, they injected
autologous MSCs to the first group, allogeneic MSCs to the second, and no
MSCs to the third one. They observed that both autologous and allogeneic
groups showed an improvement in the neurological signs of pelvic limbs
compared with the control group. These findings were corroborated with
magnetic

resonance

imaging,

histopathological

examinations,

and

immunofluorescence analysis. It was concluded that autologous and allogeneic
MSCs transplantation can be clinically helpful therapies for spinal cord injuries.
Lim et al (Lim et al, 2007) used adult mongrel dogs to evaluate the effects of
allogeneic umbilical cord blood (UCB)-derived MSCs and recombinant methionyl
human granulocyte colony-stimulating factor (rmhGCSF) on spinal cord injuries
performed using balloon compression methods at the first lumbar vertebra. One
week after the induction of the neuronal lesions, UCB-MSCs were directly
injected into the injured site of the spinal cord and rmhGCSF was administered
subcutaneously. The dogs were divided in 5 groups: no treatment, saline
treatment, UCB-MSCs, rmhGCSF, and UCB-MSCs plus rmhGCSF (UCBG). The
results were evaluated after 2, 4, and 8 weeks after transplantation. The
investigators found no significant differences between the UCB-MSC and UCBG
groups, and between the no treatment and saline groups. In addition, there was
no evidence of regeneration of spinal cord tissue by magnetic resonance imaging
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and histology, but significant evidence of functional and sensory improvement
after allogeneic UCB-MSCs transplantation was observed. Moreover, they
noticed newly formed neuronal tissues in the injured structures of the spinal cord
in the UCB-MSC and UCBG groups. In summary, they determined that the
outcomes of this study showed that transplantation of UCB-MSCs resulted in
recovered nerve function in dogs after a spinal cord injury.
Treatment of bone defects in dogs have been described in the literature based,
mainly, on associations of cMSCs and different scaffolds. Sun et al (Sun et al,
2011) harvested and cultured bone marrow-derived MSCs from the iliac crest of
beagle dogs. The cells were pre-osteodifferentiated and seeded into a
chitosan/collagen I/β-glycerophosphate (β-GP) composite hydrogel to promote
osteogenesis. After 28 days, scanning electronic microscopy observations
indicated good spreading of bone marrow MSCs and mineral nodules were
observed in this hydrogel scaffold. The in vivo phase consisted in subcutaneous
injection

of

the

chitosan/collagen/β-GP

hydrogel

loaded

with

pre-

osteodifferentiated dog-bone marrow MSCs into nude mouse dorsum. After 4
weeks, partial bone formation was detected in the hydrogel which indicated that
chitosan/collagen/β-GP hydrogel composite could induce osteodifferentiation in
cMSCs without exposure to a continual supply of external osteogenic factors. In
conclusion, the authors stated that this hydrogel composite should be useful as a
bone regeneration scaffold. Yoshioka et al (Yoshioka et al, 2012) created
bilateral bone defect in the upper incisor regions of beagle dogs, and evaluated
bone regeneration achieved by transplantation of cMSCs derived from iliac bone
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marrow mixed with carbonated hydroxyapatite (CAP) particles. Six months after
the transplantation, absolute closure of the jaw cleft was attained on the
experimental side. Occlusal X-ray and histological examinations revealed that the
regenerated bone on the experimental side was almost equivalent to the original
bone contiguous to the jaw cleft. The researchers suggested that the application
of MSCs with CAP particles can become a new treatment modality for bone
regeneration for patients with congenital anomalies in the orofacial region such
as cleft lip and palate.
The

role

of

cMSCs in

regeneration

of

muscular tissues,

particularly

cardiomyocytes, and therefore in heart diseases has also been studied. Some
breeds of dogs, particularly the Cavalier King Charles Spaniel, are affected by
cardiac diseases such as endocardiosis or dilated cardiomyopathy that contribute
to more than 50% of mortalities in these dogs (Bonnett et al., 2005; HodgkissGeere et al, 2012). Studies like the one performed by Hodgkiss-Geere et al
(Hodgkiss-Geere et al, 2012) suggests that cMSCs-based therapy might provide
benefits to these heart pathologies. These investigators analyzed adult canine
cardiac stem cells taken from canine cardiac tissue, specifically from the right/
left atria and ventricles immediately post-mortem. They were able to isolate,
characterize, and explore the cells ability to differentiate into cardiac myocytes.
The cells were exposed to four differentiation protocols and demonstrated the
following marker profile: stem cell marker c-kit and early cardiac differentiation
markers GATA 4 and flk-1, positive; the cardiomyocyte marker cardiac troponin T
and another early cardiac differentiation marker, NKx2.5, low. Gene expression
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studies demonstrated that cardiac directed differentiation was partially achieved,
with up-regulation of cardiac troponin T and NKx2.5, and down-regulation of c-kit
and endothelial lineage markers. However the cells did not express the
ryanodine

receptor

or

β1-adrenergic

receptors

and

did

not

contract

spontaneously. Based on these results, the authors concluded that the canine
heart has a reliable and reproducible resident population of adult stem cells, and
that, even though, complete differentiation was not achieved and key
components of the contractile machinery were not detected, the study could
achieve a comprehensive characterization of canine cardiac stem cells and
serves as a foundation for further studies about optimizing conditions needed for
cardiac differentiation. In an earlier study, Silva et al (Silva et al, 2005) showed
that, in a canine chronic myocardial ischemia model, the intramyocardial
injections of bone marrow-derived MSCs resulted in differentiation of those cells
into smooth muscle and endothelial cells that translated to increased vascularity
and improved cardiac function. In conclusion, they suggested that, with further
investigation, the MSC transplantation might become an alternative therapy for
ischemic heart failure.
The combination of genetic engineering and cell transplantation provides a novel
promise for diabetes treatment. Some reports in the literature have investigated
these optional therapies using cMSCs. In a diabetes study, by Zhu et al (Zhu et
al, 2011), bone-derived Beagle canine mesenchymal stem cells were isolated,
expanded, and transfected with a recombinant retroviral plasmid containing
human insulin and enhanced green fluorescent protein (EGFP). Then the cells
52

were transplanted into the livers of diabetic Beagle dogs by arterial intervention
technique. EGFP was used as the radiotracer to detect the insulin secretion, the
colonization of bone marrow derived-MSCs (BMSCs), and the long-term effects
of BMSCs on experimental animals. The variations of body weight, blood
glucose, serum insulin levels, and plasma C-peptide were determined after
autotransplantation. An increase in the body weight, a decrease in blood glucose
levels, and a reduction in the need for insulin injections were reported, but no βpancreatic cell regeneration was observed. As a general conclusion, the authors
expressed that experimental diabetes could be relieved effectively by intrahepatic
autotransplantation of BMSCs expressing human insulin, which implies a new
strategy of gene therapy for type I diabetes.
Continuing preclinical and clinical trials are necessary in canine medicine. Dogs
are considered to be a superior animal model for humans; therefore, advanced
state-of-art research in this field will benefit both dogs and humans.

2 RESEARCH AIMS
2.1 Purpose
Investigation of mesenchymal stem cell-based therapies such as bone tissue
engineering procedures and regenerative medicine has gained increasing
importance in both human and veterinary medicine. There are many properties of
mesenchymal stem cells (MSCs) that make their use an attractive option for
clinical applications. The body of studies on MSCs has focused on cells isolated
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from humans and murine models. Among other organisms, dogs are recognized
to be a suitable model for MSC studies due to their anatomical, biochemical,
physiological, and pathophysiological characteristics. Increasing veterinary
clinical trials involving canine subjects will provide unique more opportunities to
assess both the efficacy and safety of adult stem cell therapies that can be
translated to human medicine. Nevertheless, detailed knowledge of biology of
canine MSCs (cMSCs) has not been completely elucidated. The effect of many
factors such as anatomical site, passage number, culturing protocols, and donor
characteristics of cells from canine origin still remain unclear. Further
understanding of cMSC biology will provide valuable information to refine cellbased therapies such as donor graft selection for bone regeneration in veterinary
as well as human medicine.
The main purpose of this study was to characterize cMSCs isolated from beagle
dogs based on proliferative and multipotent differentiation properties.

2.2 Specific aims
This study intends to characterize cMSCs through the following specific
objectives;
1) To evaluate in vitro expansion and proliferative potential of cryopreserved
cMSCs from two different anatomical sites: orofacial region (mandible) and
appendicular bone (femur).
2) To investigate and compare in vitro differentiation potential of cMSCs into
distinct cellular lineages, namely osteogenic, adipogenic, chondrogenic,
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and neurogenic, from two different anatomical sites: orofacial region
(mandible) and appendicular bone (femur).
3) To demonstrate and compare in vivo osteogenic differentiation of cMSCs
from two different anatomical sites: orofacial region (mandible) and
appendicular bone (femur).
4) To test whether mandible-cMSCs (M-CMSCs) demonstrate superior
proliferative and multipotent differentiation properties than femur-cMSCs
(F-cMSCs) from same animals.
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3 MATERIAL AND METHODS
3.1 Experiment outline

EXPERIMENT OUTLINE

M-cMSCs

F-cMSCs

PROLIFERATION/SURVIVAL

DIFFERENTIATION

 Colony Forming
Efficiency
 Population doubling

OSTEOGENESIS (in vitro and in vivo)






Alkaline phosphatase
Bone sialoprotein
Osteocalcin
Osteopontin
In vivo transplantation

ADIPOGENESIS


Oil Red O staining

CHONDROGENESIS



Alcian blue staining

NEUROGENESIS
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Immunostaining

3.2 Sample and cell culture
Canine MSCs from the mandibular body and proximal femur of 2 Beagle dogs
(ages: 3 weeks, 2 females) were previously isolated and cryopreserved in Dr.
Akintoye’s laboratory.
The primary cMSCs were further expanded in culture using growth medium
consisting of α-MEM supplemented with 10% fetal bovine serum (Atlanta
Biologicals, Lawrenceville, GA), 100 U/ml Penicillin, 100 mg/ml streptomycin
sulfate and 2 mM glutamine (Gibco, Life technologies, NY) and maintained at
370C, in humidified atmosphere of 5% CO2 and air. Non-adherent cells were
washed away, after 24 hours, with phosphate-buffered saline (PBS) and the
medium was changed every 3-4 days. At 80% of confluence, the cMSCs were
detached with 0.5% trypsin (Invitrogen-Life Technologies, Carlsberg CA and split
as detailed in experiments outlined below. Overall, the cells used in this study
were within passage 6 or lower.

3.3 Cell proliferation
The proliferation rate of cMSCs was assessed by growth curve analysis
(Akintoye et al, 2006). Cells were plated at 9.5 x 103 cells/cm2 in 6-well plates
(Coming Life Sciences, Acton, MA) in α-MEM growth medium, which was
changed twice weekly. Cells were released on days 1, 3, 6, 9, 12, and 15 and
counted using hemocytometer to plot a growth curve.
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3.4 Colony forming efficiency (CFE) assay
Colony forming efficiency assay was performed as previously described
(Akintoye et al, 2006; Volk et al, 2012). Primary cMSCs were cultured in triplicate
25 cm² plastic culture flasks at 10¹, 10² and 10³ cells/flask with non-osteogenic
growth medium. Cells were fixed on day 14 with 100% methanol, subsequently
stained with methyl violet (Sigma-Aldrich, St Louis, MO) and aggregates of 50 or
more cells were counted as colonies.

3.5 Life span measurements
Long term survival of cMSCs was assessed by population doublings (PD) as
previously described (Akintoye et al, 2006). Cells were plated at 1 x 10⁶
cells/flask, and PD was calculated from generation number after repeated cell
passage at 1:10 split ratio until the cells attained replicate senescence.

3.6 Canine telomerase activity assay
The presence of canine telomerase reverse transcriptase (cTERT) was
determined by Western blotting of nuclear extracts isolated with Nuclei EZ Prep
Isolation Kit according to the manufacturer’s protocol (Sigma-Aldrich). Nuclear
extracts were obtained at different passages during the population doubling
experiment above. Culture dishes were washed with Dulbecco’s Phosphate
Buffered Saline and the cells were harvested by using Nuclei EZ lysis buffer. The
entire cell lysates were centrifuged at 3000 rpm, and the clear supernatant was
aspirated, conserving the nuclei pellet on ice. The supernatant contains
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cytoplasmic components and was saved for later analysis. Nuclei pellets were
resuspended in Nuclei lysis buffer, and centrifuged again. After this, the nuclei
pellets were resuspended in Nuclei EZ storage and frozen at -80 °C to be used in
the next steps. Equal amounts of nuclear extracts were used to evaluate
expression levels of monoclonal antibody to cTERT. The blots were probed with
rabbit polyclonal telomerase reverse transcriptase antibody (Novus Biologicals)
at 1:1000.This primary antibody was followed by anti-rabbit (1:2000) as
secondary antibody. Probing of blots with anti β-actin (1:2000) served as loading
control. Immunoreactive bands were analyzed digitally with Kodak Image Station
4000MM.

3.7 In vitro osteogenic differentiation
Osteogenic differentiation was performed as previously described (Volk et al,
2005; Volk et al, 2012). Canine MSCs were cultured at 1 x 104 cells/cm2 in 10
sixty mm dishes (Corning Life Sciences, Acton, MA) with α-MEM growth medium
without osteogenic inducers until they reached confluence. Half of the dishes
(n=5 dishes) were pre-coated with poly-L-lysine (Sigma-Aldrich) to enhance cell
attachment under long-term culture. At confluence, the cells in coated dishes
were exposed to osteogenic medium containing supplements of 100 ng/ml of
human bone morphogenetic protein-2 (BMP-2, GenScript, Piscataway, NJ, USA)
and 100 µM L-Ascorbic acid 2-phosphate (10−4 M) for 7 and 14 days. Medium
was changed twice weekly. Cells in the other set of dishes (n=5) were cultured in
α-MEM growth medium without inducers and used as control. At 7 and 14 days
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protein lysate and RNA were collected in parallel experimental culture dishes.
Total protein amount from lysates was determined using the Bicinchoninic acid
protein assay (Pierce™ BCA Protein Assay Kit). Equal (50 μg) protein amount
was loaded on a 4 – 20% gradient gel and transferred on nitrocellulose
membrane for western blotting. The membranes were probed with the following
primary antibodies: rabbit anti-bone sialoprotein (BSP) polyclonal antibody (Bioss
Inc.) at 1:200; rabbit anti-osteocalcin (OCN) polyclonal antibody (Bioss Inc.) at
1:200; rabbit anti-osteopontin (OPN) antibody (Rockland Inc.) at 1:500, and
rabbit anti-alkaline phosphatase (ALP) antibody (Novus Biologicals) at 1:800.
Primary anti β-actin (1:1000) and anti-α-tubulin (1:200) served as loading
controls. Furthermore, the primary antibodies were reacted with anti-mouse or
anti-rabbit secondary antibodies at concentrations ranging from 1:1000 – 1:3000.
Digital analysis of immunoreactive bands was performed using with Kodak Image
Station 4000MM (Molecular Imaging Systems, Carestream Health, Rochester,
NY).

3.8 Isolation of RNA and Real-Time Quantitative Reverse TranscriptionPolymerase Chain Reaction (RT-PCR)
Total RNA was isolated from osteogenenically-induced and control cells using
TRI Reagent® (Sigma-Aldrich). First strand cDNA was prepared with first strand
SuperScript™

Double-Stranded

cDNA

Synthesis

Kit

(Invitrogen

Life

Technologies, Carlsbad, CA) using an oligo-dT primer. Two microliters of first
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strand cDNA was added to a total volume of 50 μl PCR buffer containing: 1.5 mM
MgCl2, 200 μM dNTP, 2.5 U Taq DNA polymerase (Promega, Madison, WI) and
200 nM of each primer set. Real-time PCR was performed with 7300 Fast RealTime PCR system (Applied Biosystems, Foster City, CA) using the STBR Green
Master Mix (Applied Biosystems, Foster City CA) and the following customdesigned primers:
Canine BSP - forward 5’-TTGCTCAGCATTTTGGGAATGG-3’;
Canine BSP – reverse 5’-AACGTGGCCGATACTTAAAGACC-3’;
Canine Osteocalcin – forward 5’-CTG GTCCAGCAGATGCAAAG-3’;
Canine Osteocalcin – reverse 5’-CCGCTTGGACACGAAGGTT-3’;
Canine ALP - forward 5’-TTCAAACCGAGACACAAGCAC T-3’;
Canine ALP – reverse 5’-GGGTCAGTCACGTTGTTCCTGT-3’;
Canine Osteopontin - forward 5’-CGAGTCTGATGAATCCGATGA A-3’;
Canine Osteopontin – reverse 5’-TTGGGTTGCTGGAATGTCAGT-3’.
Gene expression levels were normalized to the housekeeping gene:
Canine β2 microglubulin - forward 5’-TCACGACACCCAGCAGAGAA-3’;
Canine β2 microglubulin – reverse 5’-GGAACCCTGACACGTAGCAGTT-3’.

3.9 In vivo osteogenesis by transplantation into immunocompromised host
Bone regenerative capacity of femur and mandible cMSCs was evaluated using
the mouse model of in vivo bone formation in immunocompromised hosts

as

described by Akintoye et al (Akintoye et al, 2006). The animal protocol was
approved by the University of Pennsylvania Office of Regulatory Affairs.. Non61

induced and osteogenically induced mandible and femur MSCs were
transplanted into separate subcutaneous pockets of three different animals as
follows:

2 × 10⁶

cMSCs

were

attached

to

40

mg

spheroidal

hydroxyapatite/tricalcium phosphate (particle size 0.5–1.0 mm, Zimmer, Warsaw,
IN) and transplanted into separate subcutaneous pockets aseptically created in
4-week-old immunocompromised nude female mice (NIH-III NU/NU, Charles
River Laboratories, Wilmington, MA). Transplants were harvested at 6, 8 and 12
weeks, fixed in 4% paraformaldehyde for 48 hours, decalcified in 10% EDTA (pH
8.0) and embedded in paraffin. Five-micrometer sections were deparaffinized,
stained with hematoxylin/eosin, and semi-quantitative bone formation was
scored, microscopically, by four blinded independent observers as previously
described (Akintoye et al, 2006). Bone scores, that were performed by the four
observers, ranged from 0 (no bone observed within the transplant), 1 (minimal
amount of bone), 2 (weak bone formation occupying only a small portion of the
transplant), 3 (moderate bone formation occupying a significant portion but less
than 50% of the transplant) and 4 (abundant bone formation, occupying more
than 50% of the transplant).

3.10 Adipogenic differentiation
Adipogenic differentiation was induced as previously described (Akintoye et al,
2006; Volk et al, 2012). cMSCs were cultured at 1.8 x 10³ cells/cm 2 in 4-well
chamber slides (Coming Life Sciences, Acton, MA) using α-MEM growth medium
without adipogenic inducers. At approximately 100% confluence, the growth
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medium was switched to adipogenic medium containing supplements of 10 −8 M
dexamethasone, insulin (1 μg/ml), 1-methyl-3-isobutylxanthine (IBMX, 5 × 10−8
M), indomethacin (10−4 M), and fetal bovine serum (FBS) 10% for 15 days;
medium was changed twice weekly. Similar culture plates without exposure to
adipogenic medium served as control. At 15 days, the cells were rinsed with 2x
phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 10 minutes
at room temperature, stained with 0.3% Oil Red O for 1 hour, and counterstained
with 1% Fast green dye for 10 minutes. The slides were mounted with coverslip
and lipid droplets were identified and quantified microscopically. Using Image J,
lipid droplets were counted for the cell types, femur and mandible, non-induced
and induced cells, and then the number of droplets per cell was calculated.

3.11 Chondrogenic differentiation
Chondrogenesis differentiation assay was performed as previously described
(Csaki et al, 2007; Park et al, 2012; Volk et al, 2012). Chondrogenic
differentiation was induced using the pellet method. cMSCs were cultured in 75
cm² flasks at 75 x 10⁴ cells/cm² until they reached 80-90% confluence. Then, the
cells were trypsinized and counted with hemocytometer. 2 x 10⁶ cells were
transferred into various 15 ml polypropylene tubes. The cells were centrifuged to
a pellet form, and supernatant was aspirated without disturbing the pellets.
Thereafter, the pellets were washed with PBS, then cultured in chondrogenic
medium consisting of alpha-MEM. supplemented with 10−8 M dexamethasone,
ITS+ 1%, L-Ascorbic acid 2-phosphate (10−4 M), transforming growth factor-beta
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3 (TGF-β3) 10ng/ml, β-glycerophosphate 10mM, glutamine 2 mM, penicillinstreptomycin sulfate 100 U, and pyruvate 2 mM. Cell pellets cultured with growth
medium without chondrogenic inducers were used as control. Chondrogenic
medium was replenished every 2-3 days. The pellets were harvested after 4 and
8 weeks for histological analysis, Pellets were fixed with 4% paraformaldehyde
for 12 hours, and processed for paraffin embedding. 5 µm sections were, stained
with Alcian blue solution, counterstained with nuclear fast red solution,
dehydrated, and mounted with coverslip for histological evaluation.

3.12 Neural differentiation
Canine MSCs were cultured at 4 x 10³ cells/cm2 in 8-well chamber slides coated
with collagen (Corning® BioCoat™) with normal α-MEM growth medium without
inducers until they reached confluence. Thereafter, 4 chambers were exposed to
neurogenic medium, and the other 4 were kept in normal growth medium as the
control group. Neurogenically induced cells were pre-incubated for 24 hr. with αMEM medium supplemented with 20% fetal bovine serum (Atlanta biological,
Lawrenceville, GA), 100 U/ml Penicillin, 100 mg/ml streptomycin sulfate, 2 mM
glutamine (Gibco, Life technologies, NY), and 10 ng/ml β-fibroblast growth factor
(β-FGF, 10 ng/ml) (BD Biosciences) while control cells were still retained in αMEM growth medium without β-FGF. The pre-induction medium was then
removed, and the cells were washed with PBS and transferred to neuronal
induction medium composed of: α-MEM supplemented with 20% fetal bovine
serum, 100 U/ml Penicillin, 100 mg/ml streptomycin sulfate, 2 mM glutamine
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(Gibco, Life technologies, NY), 2% dimethyl sulfoxide (DMSO; Sigma-Aldrich), 10
ng/ml fibroblast growth factor (FGF, 10 ng/ml), 200 μM butylated hydroxyanisole
(BHA; Sigma-Aldrich), 10 µM Forskolin (Sigma), 25 mM KCl, 2 mM Valproic acid
(Calbiochem), and 5 µg/mL insulin. Cells were incubated for 24 hours, 4, 7, and
14 days at 37ºC in a humidified 5% carbon dioxide environment. Neural
differentiation was evaluated using morphological analysis and immunostaining.
Early neuronal expression was assessed with anti-nestin polyclonal antibody
(LifeSpan BioSciences, Inc.), while late neuronal expression was assessed with
anti-beta III tubulin (Bioss). Cells were fixed with 4% paraformaldehyde,
incubated in 0.1% TritonX-100 for 5 minutes, blocked with 3% goat serum for 30
minutes, and incubated overnight with primary antibodies: 1:200 dilution of antinestin and 1:200 anti-beta III. After washing, the samples were incubated with
1:500 dilution of fluorescent-labeled secondary antibody goat anti-rabbit Alexa
Fluor 555 (Life Technologies). Nuclei were visualized with 1 ųg/ml of Hoeschst
33342.

Specimens were serially excited and images were captured on the

microscope.

3.13 Statistical analysis
All experiments were performed at least three times; each cell type (induced and
control) were tested in triplicates, and the resulting data was averaged prior to
subsequent analysis. The results were expressed as mean ± standard deviation.
Comparison of responses between mandible-cMSCs and femur-cMSCs was
measured by the paired t-test analysis and values of p<0.05 were considered
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statistically significant. Cell proliferation was tested by analyzing slopes of linear
regression lines of mandible and femur cells. A value of p<0.05 was also
considered statistically significant.

4 RESULTS
4.1 Cell culture of cMSCs
The

primary

F-cMSCs

and

M-cMSCs

expanded

in

culture

displayed

characteristic polymorphic, fibroblast-like morphology in monolayer culture, as is
shown by M-cMSCs (Figure 4). Within about 5 to 6 days, the M-cMSCs were
usually 80-90% confluent, while F-cMSCs were comparatively at 60-70%.

Figure 4

20x
Figure 4: Representative image of M-cMSCs monolayer showing
characteristic fibroblast-like morphology.
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4.2 Cell proliferation

When cMSCs were plated at low densities of 95,115 cells/cm 2 and counted at
days 1, 3, 6, 9, 12, and 15, M-cMSCs displayed significant higher proliferative
rates until day 9 compared with those of F-cMSCs. A test of slopes demonstrated
that the differences between both slopes, mandible and femur, were very
significant (p= 0.006). Additionally, while F-cMSCs proliferation plateaued at day
9, the M-cMSCs continued to grow exponentially before plateauing by day 12
(Fig. 5).
Figure 5

p = 0.006

Figure 5 Cell proliferation: the slope representing the number of mandible
cells until day 9 was significant different (p = 0.006) compared with that of
femur cells, demonstrating that M-cMSCs had higher proliferative rate than
F-cMSCs. After day 9, the proliferative capacity of both cell types started
decreasing.
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4.3 Colony forming efficiency assay
Cells isolated from femur and mandible were apparently similar in terms of their
ability to form colonies, which were visualized and counted after being stained
with methyl violet (Figure 6).
Figure 6

A

B

F-cMSCs

M-cMSCs

Figure 6 Colonies in plastic flasks A: F-cMSCs B: M-cMSCs. Arrows indicate
stained cell colonies of both cell types.

Mean colony forming efficiency per 10⁵ nucleated cells was not significantly
different between F-cMSCs and M-cMSCs (Figure7)
Figure 7
Number of CFUs per 10⁵ cells
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Figure 7 Mean colony forming units per 10⁵ nucleated cells was not significantly different
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between F-cMSCs and M-cMSCs.

4.4 Population doubling and telomerase activity
Life span of cMSCs assessed by population doublings (PDs) capacity
demonstrated that M-cMSCs were able to survive until passage 12, which relates
with a total of 77 days after repeated passaging, but F-cMSCs reached
replicative senescence at passage 6, which occurred 10 days earlier than McMSCs (Fig. 8). Since this experiment was performed in duplicates, a statistic
analysis was not possible to be performed. However, qualitatively and as
mentioned above, mandible cells survived more days compared with femur cells.

Figure 8
Mean number of cells
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Figure 8 Life span: M-cMSCs were able to survive five more passages
relative to F-cMSCs

To complement lifespan assessment canine telomerase reverse transcriptase
(cTERT) activity was evaluated by Western blotting of nuclear extracts isolated at
different passages of the population doubling experiment. The expression of
cTERT progressively decreased as the cells progressed toward senescence as
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demonstrated

by

immunoreactivity

and

quantitative

analysis

of

the

immunoreactive bands. (Fig 9A-B) While F-cMSC TERT was quantitatively
higher at baseline and subsequent passages, the expression was more shortlived relative to M-cMSCs (Fig. 9B).
Figure 9A

Passages of F-cMSCs

P1

P2 P3 P4

Passages of M-cMSCs

P1 P2 P3 P4 P5 P6 P7 P8

293T

cTERT

cTERT

β-Actin

β-Actin

Figure 9A Immunoreactive bands of canine telomerase obtained through Western blot
progressively decreased for both, femur and mandible cells with subsequent passages. βactin served as loading control and 293T cells as control for expression of cTERT.

Canine TERT expression level relative to
baseline

Figure 9B
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Figure 9B Expression of canine TERT relative to baseline: the expression of cTERT was
downregulated as the cells progressed toward senescence. F-cMSCs demonstrated a
more short-lived expression compared with m-cMSCs..
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4.5 In vitro osteogenesis

Time-dependent in vitro osteogenic properties of both induced, M-cMSCs and FcMSCs showed increased expression levels of early osteogenic markers such as
alkaline phosphatase (ALP) and bone sialoprotein (BSP) compared with noninduced cells. These findings are representative of, at least 3 different
experiments. Interestingly, induced mandible cells displayed active expression of
ALP at 7 days of induction, which showed their initial response to osteogenic
differentiation. In addition, on day 14 mandible cells exhibited a significant upregulation of ALP (p= 0.04) compared with femur cells. As expected, both cell
types showed maximal ALP expression on day 7 (Figure 10).

F-cMSCs
Control

14 days

7 days

Figure 10

Osteo

M-cMSCs
Control

Osteo

F-cMSCs
Control

M-cMSCs

Osteo

Control

Osteo

ALP

Fold change ALP
(normalized to actin and
control)

β-actin

4
3

7 days
14 days

2
7 days p= 0.2

1
14 days p= 0.004

0
F-cMSCs

MSC types

M-cMSCs

Figure 10 Alkaline phosphatase expression at 7 and 14 days of osteogenic
induction: Although at 7 days the difference was not statistically significant, McMSCs demonstrated higher expression levels of ALP at 7 and 14 day time
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points compared with F-cMSCs.

In relation to BSP expression at 7 and 14 days of osteogenic induction, there was
a higher time-dependent BSP expression in mandible cells relative to femur cells.
As with ALP, there was a statistically significant up-regulation (p= 0.05) of BSP in
mandible cells at day 14 compared with cells from femoral origin (Figure 11).

14 days
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Figure 11
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Figure 11 Bone sialoprotein expression at 7 and 14 days of osteogenic
induction: there was a higher time-dependent BSP expression in M-cMSCs
relative to F-cMSCs based on 7 and 14 days.
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While there were no differences in osteopontin (OPN) expression levels between
the two cell types, osteocalcin (OCN) was not expressed early by F-cMSCs
compared to M-cMSCs that consistently demonstrated measurable levels of the
late osteogenic marker OCN at both 7 and 14 days. (Figures 12 and 13).

Figure 12
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Figure 12 Osteopontin expression at 7 and 14 days of osteogenic induction: there
was not difference in OPN expression at 7 and 14 days between the two types of
cells.
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Figure 13
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Figure 13 Osteocalcin expression at 7 and 14 days of osteogenic induction: while
there was no early expression of OCN in F-cMSCs, it was significantly upregulated
in M-cMSCs relative to F-cMSCs at 7 and 14 days.
4.6 Reverse transcriptase polymerase chain reaction (RT-PCR)

Gene transcripts of ALP, BSP, OPN and OCN were also assessed by real-time
RT-PCR in cMSCs exposed to osteogenic and non-osteogenic conditions. Gene
expressions of ALP, BSP, and OCN were significantly up-regulated in mandible
compared with femur cells at 7 and 14 days of induction (p values indicated in
the respective graphs). These findings were consistent with Western blot results.
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Differences between the two cell types were more clearly defined after 14 days of
osteogenic stimulation based on significantly upregulated expression levels of
ALP, BSP and OCN in M-cMSCs relative to F-cMSCs. Interestingly, OPN gene
transcript was only moderately upregulated in M-cMSCs at day 7 (Fig 14 - A, B,
C, D).
7 d p= 0.02

Figure 14
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Figure 14 Real time PCR; gene expressions of ALP (A) and BSP (B) were significantly
upregulated in M-cMSCs compared to F-cMSCs at 7 and 14 days of induction. In terms of
transcription of OCN (C), it was also upregulated in M-cMSCs relative to F-cMSCs at both
time periods. However,OPN (D) expression moderately increased at 7 days in M-cMSCs
compared to F-cMSCs.
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4.7 In vivo osteogenesis

Bone forming capacity of cMSCs assessed by in vivo transplantation showed
microscopically observable bone nodules in hematoxylin/eosin stained sections
after 6, 8, and 12 weeks (Figures 15-20). Semi-quantitative analysis using an
established bone scoring system (Akintoye et al, 2006) showed that bone
formation capacities of M-cMSCs and F-cMSCs were not different between noninduced and osteogenically-induced cells (Fig 21).
Figure 15
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Figure 15 In vivo bone regeneration after 6 weeks transplantation: hematoxylin
and eosin stained sections of bone formed in vivo by non-induced and
osteogenically-induced F-cMSCs. Both cell types, non-induced and induced,
demonstrated bone formation (woven bone) (B= bone; FT; fibrous tissue; HA:
hidroxyapatite/tricalcium phosphate carrier; Oc; osteocyte).
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Figure 16
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Figure 16 In vivo bone regeneration after 6 weeks transplantation: hematoxylin and eosin
stained sections of bone formed in vivo by non-induced and osteogenically-induced McMSCs. Both cell types, non-induced and induced, demonstrated bone formation (woven
bone) (B= bone; FT; fibrous tissue; HA: hidroxyapatite/tricalcium phosphate carrier; Oc;
osteocyte).
Figure 17
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Figure 17 In vivo bone regeneration after 8 weeks transplantation: hematoxylin and eosin
stained sections of bone formed in vivo by non-induced and osteogenically-induced FcMSCs. Both cell types, non-induced and induced, demonstrated bone formation (woven
bone) (B= bone; FT; fibrous tissue; HA: hidroxyapatite/tricalcium phosphate carrier; Oc;
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osteocyte; HP: hematopoiesis).

Figure 18
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Figure 18 In vivo bone regeneration after 8 weeks transplantation: hematoxylin and eosin
stained sections of bone formed in vivo by non-induced and osteogenically-induced McMSCs. Both cell types, non-induced and induced, demonstrated bone formation (woven
bone) (B= bone; FT; fibrous tissue; HA: hidroxyapatite/tricalcium phosphate carrier; Oc;
osteocyte).
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Figure 19
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Figure 19 In vivo bone regeneration after 12 weeks transplantation: hematoxylin and eosin
stained sections of bone formed in vivo by non-induced and osteogenically-induced FcMSCs. Both cell types, non-induced and induced, demonstrated bone formation (woven
bone) (B= bone; FT; fibrous tissue; HA: hidroxyapatite/tricalcium phosphate carrier; Oc;
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osteocyte; HP: hematopoiesis;
Ad: adipose tissue).

Figure 20
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Figure 20 In vivo bone regeneration after 12 weeks transplantation: hematoxylin and eosin
stained sections of bone formed in vivo by non-induced and osteogenically-induced McMSCs. Both cell types, non-induced and induced, demonstrated bone formation (woven
bone) (B= bone; FT; fibrous tissue; HA: hidroxyapatite/tricalcium phosphate carrier; Oc;
osteocyte).
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Figure 21
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Figure 21 In vivo bone regeneration: hematoxylin and eosin stained-sections of
bone formed in vivo by osteogenically-induced cMSCs transplanted in the subcutis
of immunocompromised nude mice. Both types of cells, mandible and femur and
non-induced and induced, formed bone independently of the duration of the
transplants.

4.8 Adipogenic differentiation

After 15 days of adipogenic induction, non-induced and induced cMSCs were
stained with Oil Red O and observed microscopically to assess lipid droplets
within cytoplasm. Cell cultures treated with adipogenic induction media were
found to contain greater accumulation of lipid-rich vacuoles within cells compared
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to the untreated control cells. Oil Red O staining for fat revealed that these
vacuoles contain neutral lipids consistent with adipocyte phenotype. By
visualization, M-cMSCs showed more numerous lipid clusters and larger in size
than those of femur cells. This demonstrates that adipogenic differentiation of the
mandible cells was apparently more efficient (Figure 22).
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Figure 22
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Figure 22 Adipogenesis: Oil Red O staining revealed cytoplasmic lipid inclusions in
both cells, F-cMSCS and M-cMSCs, cultured in the presence of adipogenic
inducers, as compared to cells cultured under control conditions. More abundant
lipid droplets were observed in M-cMSCs relative to F-cMSCS.

After counting the lipid droplets for both cell types, the mean of lipid vacuoles per
cell was higher in cells under adipogenic induction, femur and mandible, relative
to non-induced cells. Additionally, mandible cells exhibited a significant (p=
0.007) higher number of lipid droplets compared with femur cells, which is
consistent with the visualization assessment (Figure 23).
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Figure 23

Mean lipid droplets per cell

16.00
Non-induced

12.00

Induced

8.00
p = 0.007

4.00

0.00

F-cMSCs

M-cMSCs
Cell type

Figure 23 Mean lipid droplets per cell: induced cells, femur and mandible displayed
higher number of lipid droplets per cell. Induced M-cMSCs showed significant
higher number of lipid vacuoles than F-cMSCs (p= 0.007).

4.9 Chondrogenic differentiation

The chondrogenically-induced and non-induced pelleted cMSCs were assessed
histologically using Alcian Blue staining after 4 and 8 weeks of pellet culture.
Comparatively, chondrogenically-induced cells displayed significant higher
number of chondrocyte-like cells per unit area based on pink to red staining
patterns (Figures 24-25). M-cMSCs were more responsive to chondrogenic
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induction especially after 4 weeks because the tissue sections showed
apparently more chondrocytes per unit area (p = 0.009) (Figure 26).

F-cMSCs

Figure 24

8 weeks

Non-induced

4 weeks

Chondrogenesis

CD

Figure 24 Chondrogenesis differentiation F-cMSCs:
microphotographs showed an increased number of
chondrocytes stained with alcian blue technique, in cell
cultures under chondrogenic induction than cells under noninduced conditions; CD: chondrocyte.
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Figure 25

M-cMSCs
8 weeks

Chondrogenesis

Non-induced

4 weeks

CD

Fig.
25
Chondrogenesis
differentiation
M-cMSCs:
microphotographs showed an increased number of
chondrocytes stained with alcian blue technique, in cell
cultures under chondrogenic induction than cells under noninduced conditions. In addition, a higher number of
chondrocytes was observed in M-cMSCs compared to FcMSCs; CD: chondrocyte.
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Figure 26
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Fig. 26 Mean of chondrocytes per unit area for F-cMSCs and M-cMSCS: both types of
cells demonstrated a significant higher number of chondrocytes at 4 and 8 weeks
under induced conditions relative to non-induced conditions. At 4 weeks, there was a
significant (p=0.009) higher number of chondrocytes in induced M-cMSCs compared
to F-cMSCs.

4.10 Neurogenic differentiation
After 24 hours, 4, 7, and 14 days of neurogenic induction, the cMSCs were
immunostained with two neuronal markers; nestin and βIII-tubulin. Neurogenic
culture medium induced spindle-shaped morphological changes (Figures 27-36)
as early as 24 hours post-induction. Long-term neural stimulation further induced
cMSCs to acquire long cytoplasmic processes and neuron-like morphology with
characteristic dendritic shape (Figures 27-36). The neuronally-induced cells were
slightly more reactive to both neuronal markers: nestin and βIII tubulin.
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Figure 27

F-cMSCs

Control

F-cMSCs
Induced

Control

Induced

10x

20x

24 hours

4 days

Figure 27 Neurogenesis-nestin 24 hours and 4 days induction: after neural induction,
induced F-cMSCs changed morphologically into a spindle shape. The induced cells
acquired more long fibroblastic neuronal extensions, mimicking a dendritic shape, than
control cells.
Figure 28

F-cMSCs

F-cMSCs
Induced

Control

Induced

Control

10x

20x

7 days

14 days

Figure 28 Neurogenesis-nestin 7 and 4 days induction: Induced F-cMSCs continued to
undergo spindle-shaped morphological changes. There was similar expression of nestin by
non-induced and induced cells.
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Immunostaining of non-induced and induced F-cMSCs with no primary antibody
(anti-nestin) included showed no expression or extreme decreased expression of
nestin (Figure 29).

Figure 29

F-cMSCs
Control

Induced

10x

20x

Figure 29 Negative control of neurogenesisnestin in non-induced and induced F-cMSCs:
immunofluorescence
microphotographs
showing no expression or extreme decreased
expression
of the primary antibody antinestin.
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Figure 30

M-cMSCs

Control

M-cMSCs
Induced

Control

Induced

10x

20x

24 h

4 days

Figure 30 Neurogenesis-nestin 24 hours and 4 days induction: after neural induction,
induced M-cMSCs changed morphologically into a spindle shape. The induced cells
acquired more long fibroblastic neuronal extensions, mimicking a dendritic shape, than
control cells.
Figure 31

M-cMSCs
Induced

Control

M-cMSCs
Control

Induced

10x

20x

7 days

14 days

Figure 31 Neurogenesis-nestin 7 and 14 days induction: Induced M-cMSCs
continued to undergo spindle-shaped morphological changes. There was similar
expression of nestin by non-induced and induced cells..
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Immunostaining of non-induced and induced M-cMSCs with no primary antibody
(anti-nestin) included showed no expression or extreme decreased expression of
nestin (Figure 32).

Figure 32

M-cMSCs
Control

Induced

10x

20x

Fig. 32 Negative control of neurogenesis-nestin in
non-induced and induced M-cMSCs:
immunofluorescence microphotographs showing
no expression or extreme decreased expression
of the primary antibody anti-nestin.
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F-cMSCs

Figure 33
Control

F-cMSCs
Induced

Control

Induced

10x

20x

7 days

14 days

Figure 33 F-cMSCs neurogenesis βIII-tubulin 7 and 14 days induction:
immunofluorescent microphotographs of F-cMSCs stained with primary antibody against
βIII-tubulin showed that induced cells adopted more neural-like features than control
cells. However, control and induced cells demonstrated similar expression of βIII-tubulin.

Immunostaining of non-induced and induced F-cMSCs with no primary antibody
(anti- βIII-tubulin) included showed no expression or extreme decreased
expression of βIII-tubulin (Figure 34).
F-cMSCs

Figure 34
Control

Induced

10x

20x

Figure 34 Negative control of neurogenesis- βIII-tubulin in non-induced and induced FcMSCs: immunofluorescence microphotographs showing no expression or extreme
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decreased expression of the primary
antibody anti-βIII-tubulin.

Figure 35

M-cMSCs

M-cMSCs
Induced

Control

Control

Induce
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10x

20x
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Figure 35 M-cMSCs neurogenesis βIII-tubulin 7 and 14 days induction:
immunofluorescent microphotographs of M-cMSCs stained with primary antibody against
βIII-tubulin showed that induced cells adopted more neural-like features than control
cells. However, control and induced cells demonstrated similar expression of βIII-tubulin.

Immunostaining of non-induced and induced M-cMSCs with no primary antibody
(anti- βIII-tubulin) included showed no expression or extreme decreased
expression of βIII-tubulin (Figure 36).
M-cMSCs

Figure 36

Control

Induced

10x

20x

Figure 36 Negative control of neurogenesis- βIII-tubulin in non-induced and induced
M-cMSCs: immunofluorescence microphotographs showing no expression or
extreme decreased expression of the
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primary antibody anti-βIII-tubulin.

5 DISCUSSION

Safety and efficacy of new MSC-based therapies for humans must be assessed
using two animal species: rodents, usually as first group, and a non-rodent large
animal as second group (de Bakker et al, 2014). As stated, MSCs can be
isolated from unconventional model organisms such as dogs, cats, goats,
rabbits, cattle, sheep, horses, guinea pigs (Calloni et al, 2014). Based on their
anatomical, pathological, biochemical and physical characteristics, dogs (Canis
familiaris) are recognized to be reliable and attractive models to assess MSCbased regenerative medicine and tissue engineering. These advancements
result in great benefits for translational studies in human medicine, as well as the
obvious impact on cutting edge veterinary therapies (de Bakker et al, 2014; Volk
et al, 2012). However, with respect to canine medicine and MSC-based
therapies, there are still many unknown factors. For example, studies on ideal
number of cells in transplantation and skeletal site-specific characterization of
canine stem cells from the orofacial region and axial/appendicular bones have
not been addressed yet.
In vitro and in vivo trials with cMSCs have used different tissues and anatomic
regions as donor sites: adipose tissue (Kisiel et al, 2012; Vieira et al, 2010;
Martinello et al, 2011; Neupane et al, 2008; Reich et al, 2012; Requicha et al,
2012), umbilical cord tissue (Seo et al, 2009), umbilical cord blood (Seo et al,
2009), bone marrow (Csaki et al, 2007; Kisiel et al, 2012, Volk et al, 2012, Volk et
al, 2005, Eslaminejad and Taghiyar, 2010, Mathieu et al, 2009, Tharasanit et al,
92

2011), dental pulp (Dissanayaka et al, 2011), periodontal; ligament (Wang et al,
2012), amniotic fluid (Uranio et al, 2011,), muscle (Kisiel et al, 2012),

and

periosteum (Kisiel et al, 2012). Isolation and characterization of cMSCs from
bone marrow have used donor sites such as long bones but rarely orofacial
region. Moreover, studies have focused their attention on the osteogenic
potential of cMSCs in vitro and in vivo (Kadiyala et al, 1997, Kang et al, 2012,
Guercio et al, 2012).
Assessing site-specific differences in cMSCs is of interest, since there are no
studies comparing, for instance, differentiation capacity of cMSCs between
orofacial region and appendicular/axial bones. Two studies have found a
significant increase in osteogenic response from bone marrow-derived human
MSCs from the orofacial region compared to those harvested from the iliac crest
(Akintoye et al, 2006; Osyczka et al, 2009). Our study tested a similar hypothesis
that cMSCs are skeletally site-specific. In support of previous studies (Csaki et
al, 2007, Kisiel et al, 2012, Volk et al, 2012); our results demonstrated that
cMSCs, that were previously collected and cryopreserved, were successfully
expanded in culture flasks. The cells were able to adhere to plastic surfaces,
grew uniformly on monolayers and adopted a fibroblastic-like morphology. These
properties, plus their multi-lineage differentiation capacity exhibited through the
expression of some osteogenic markers and morphological observations, are in
accordance with the two criteria established by the International Society for
Cellular Therapy to characterize MSCs from animal sources (Dominici et al,
2006). Previous studies have determined that cMSCs can be cryopreserved and
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still maintain their viability and be induced to differentiate along multiple lineages
(Kraus and Kirker-Head, 2006, Zhu et al, 2013).
Proliferative capacity of cMSCs
Mandible cMSCs displayed higher proliferative rates than those of the femur.
Mean number of mandible cells was consistently higher than femur cells at alltime points. Similar higher numbers were observed in the population doubling
experiment for M-cMSCs. The increased proliferative capacities of M-cMSCs
indicate more self-renewal ability than those of F-cMSCs. Unlike long bones,
bones originating from the neural crest cells, such as maxilla and mandible, do
not contain prominent hematopoietic components (McCauley and Somerman,
2012). This fact could explain the higher proliferation and population doubling of
M-cMSCs since stromal cells of non-hematopoietic marrow divide more actively
than hematopoietic cells, which are usually mitotically latent (Bianco et al, 1999).
Furthermore, F-cMSCs underwent cellular senescence earlier than M-cMSCs.
Expression of cTERT confirmed our previous findings since this enzyme was
downregulated in agreement to the increasing cell passages. The use of TERT in
our study was based on the knowledge that the tissue distribution of telomerase
activity in dogs is similar to that in humans, where it is basically restrained to
malignant cells or cells with high proliferative potential such as MSCs, and not
found in normal somatic tissues (Zavlaris et al, 2009; Argyle and Nasir, 2003).
The high specificity of the rabbit polyclonal antibody to cTERT that we used has
been shown to be as high as 92% according to Zavlaris et al (Zavlaris et al,
2009) using tumor samples Similarly Akintoye et al (Akintoye et al, 2006) has
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reported higher proliferation rate, population doubling and telomerase expression
in human orofacial MSCs relative to those of iliac crest in same individuals. The
higher telomerase expression of M-cMSCs also correlates with similarly higher
colony forming efficiency (CFE) relative to F-cMSCs. These site-dependent
differences have also been reported between cMSCs from ilium that displayed
relatively higher CFE than femur or humerus (Volk et al, 2012).
Differentiation of cMSCs
Diverse differentiation pathways of M-cMSCs and F-cMSCs were assessed
including osteogenic, adipogenic, chondrogenic and neurogenic lineages.
In vitro osteogenesis of cMSCs
The capacity of MSCs to undergo osteogenic differentiation in vitro is well
established and they externalize markers known to be expressed by bone
forming osteoblast. According to Huang et al (Huang et al, 2007) three different
stages has been observed in the cell growth of osteoprogenitors in vitro (Figure
37): (i) the first 4 days are characterized by cell proliferation where a DNA peak is
observed, (ii) from day 5 to day 14, there is an early cell differentiation where the
main osteoprogenitor cell marker is ALP. After this initial peak of ALP its level
starts to drop. Also found at an early stage is the expression of BSP, (iii) the third
stage, which occurs from day 15 to day 28, is distinguished by terminal
differentiation and matrix maturation. The main markers at this stage are
osteocalcin and osteopontin, followed by calcium and phosphate deposition. In
general, ALP rises initially before decreasing when mineralization has far
progressed; BSP is momentarily expressed at an early stage and then
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upregulated again during bone formation by differentiated osteoblasts; and
osteocalcin is associated with mineralization (Aubin, 2001).

Figure 37

Osteogenic differentiation in vitro
(Adapted from Huang et al, Tissue Engineering, 2007)

Cell proliferation
Mineralization

0

Early cell differentiation

5
DNA

Mineralization

14

28

OCN
ALP
Collagen type I matrix OPN
Calcium and
BSP
phosphate deposition

Figure 37 Osteogenic differentiation in vitro and expression of bone markers at
different periods.

As ALP is one of the earliest markers of osteoblastic cell differentiation (Choi et
al, 2011), the active expression of this marker in our study, specifically in McMSCs, on day 7 showed their responsiveness to the initiation of osteogenic
differentiation. Additionally, on day 14, M-cMSCs displayed a statistically
significant upregulation of ALP compared with F-cMSCs (p<0.05). As expected,
both cell types displayed maximal ALP expression levels on day 7 before the
slight decline on day 14. A similar trend was displayed also by BSP expression
levels.
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Osteocalcin is an important non-collagenous protein component of bone
extracellular matrix, it is considered indicator of osteoblast differentiation, and it is
produced and secreted by osteoblast in the late stage of maturation (Sila-Asna et
al, 2007; Kaveh et al, 2011). Accordingly, our observations demonstrated a
significant OC upregulation from M-cMSCs relative to F-cMSCs, and this
increase was more pronounced at 14 days of induction of mandible cells.
There were no changes at days 7 and 14 for both types of cMSCs, and
compared with the cells under non-induced media with regards to the expression
of OPN. This data could be due to possible presence of intracellular OPN. It was
first reported by Zohar et al (Zohar et al, 1997) in osteogenic cultures of fetal rat
calvarial cells. During MSC differentiation, as intracellular OPN has an effect on
the activation of mitogen-activated protein kinase (MAPK) signaling; it is possible
that OPN has effect on MSCs survival and differentiation.
In vitro osteogenic differentiation of MSCs fundamentally depends on the culture
conditions. Two common components of osteogenic induction medium are bone
morphogenetic proteins (BMPs) and glucorticoids particularly, dexamethasone.
Apparently, MSC responsiveness to osteogenic inducers is specie-specific. .
According to Volk et al (Volk et al, 2005), BMPs are effective inducers cMSC
osteogenesis.. On the other hand, dexamethasone looks to have no
osteoinductive effect and reduces BMP-stimulated osteogenesis. Moreover, the
addition of ascorbate which promotes formation of a collagen-rich matrix, to
BMP-containing medium seems to be necessary when MSCs from young dogs
are used. In this study, the authors found that combination of BMP and ascorbate
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resulted in a significant increase of ALP activity, whereas the combination of
dexamethasone and ascorbate was unsuccessful in inducing osteogenesis.
These findings are consistent with our first set of osteogenesis trials where we
used medium containing dexamethasone and ascorbate and the expression of
ALP and BSP were not increased in mandible and femur MSCs compared with
the cells maintained under non-osteogenic conditions (data not shown). But
switching to BMP-containing osteogenic medium thereafter improved osteogenic
responsiveness of cMSCs..
In vivo osteogenesis of cMSCs
While in vitro osteogenesis of M-cMSCs was apparently higher than that of FcMSCs, there were no site-related differences in in vivo bone formation by both
cell type whether induced osteogenically or not. In a study by Kang et al (Kang et
al, 2012), where osteogenic potential of cMSCs from adipose tissue, bone
marrow, umbilical cord blood, and Wharton’s jelly were compared, it was found
that the in vitro osteogenic potential presented differences among the cell types
without any significant differences in bone formation in vivo. These outcomes
suggest the osteogenic potential observed in vitro and in vivo can be slightly
different for each type of MSCs. This hypothesis is supported by Cho et al (Cho
et al, 2010) who found discrepancies of differentiation potential between in vitro
and in vivo results of differentiation in several types of MSCs.
Tissue

vascularization

plays

a

vital

role

in

osteogenesis

to

support

osteoprogenitor cell survival.(Kang et al, 2012). On the other hand, the formation
of blood vessels can be induced by the initial presence of MSCs (Kaigher et al,
98

2003) because MSCs also secrete vascular endothelial growth factor (VEGF)
that plays a central role in angiogenic response. Kang et al (Kang et al, 2012)
speculated that the results obtained in the in vivo assay where new bone
formation was similar in different types of MSCs, could be influenced by the
capacity of MSCs to promote neovascularization. Furthermore, the biochemical
and mechanical factors affecting the destiny of MSCs in their stem cell niche are
different from those used in the in vitro techniques (Birmingham et al, 2012).
While the functions of the inducers during osteogenesis in vitro has been
elucidated (Vater et al, 2011), the in vivo biochemical environment and the
driving source for the osteogenic differentiation of MSCs in their native habitat
remains unclear (Birmingham et al, 2012).
Adipogenic differentiation
Adipogenic differentiation was confirmed by the presence of Oil Red O stained
lipid vacuoles within cells cultured in adipogenic medium. These observations are
consistent with previous reports of cMSCs (Vieira et al, 2010; Csaki et al, 2007,
Kisiel et al, 2012). Cells from the mandible area seemed to have greater
adipogenic potential based on a subjectively greater number of lipid clusters
within the cells, compared with cells from femur. This is in contrast to the study
by Akintoye et al (Akintoye et al, 2006) where human MSCs from appendicular
bone such as iliac crest showed a more pronounced differentiation to adipocytes
compared with cells from the orofacial area (maxilla and mandible). Other studies
(Seo et al, 2009: Neupane et al, 2008) have reported the inability of isolated and
cultured cMSCs, in one case from adipose tissue and from umbilical cord blood
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in the other, to differentiate towards the adipogenic lineage. In the study by
Neupane et al (Neupane et al, 2008), cMSCs were found to be refractory to the
commonly used adipogenic induction media for human MSCs. After replacement
of fetal bovine serum with rabbit serum and addition of higher glucose
concentration to the medium, adipogenic differentiation was enhanced. As
demonstrated by Csaki et al (Csaki et al, 2007), in our study, adipogenesis was
induced with insulin, dexamethasone and 1-methyl-3-isobutylxanthine (IBMX).
Some investigators (Gregoire et al, 1998) have proposed that although the full
complement of inducing agents required for differentiation varies with each cell
culture model, insulin/insulin-like growth factor I (IGF-I), cyclic adenosine
monophosphate and glucocorticoids are generally considered necessary for the
induction of adipogenic differentiation either in serum-containing or in serum-free
media.
Chondrogenic differentiation
Our attempt at differentiating cMSCs into the chondrogenic lineage using
induction medium with TGFβ-3 was considered successful. Recovery of the cell
pellet culture after 4 and 8 weeks followed by Alcian blue staining revealed
intense staining of a high content of cartilage specific proteoglycans. The
presence of chondrocytes was noticed by pink or red staining of their respective
nuclei and the cells adopting rounded shape. Similar findings were described by
Csaki et al (Csaki et al, 2007), where they induced chondrogenic differentiation in
bone marrow-derived MSCs. In contrast to this, control cultures showed little or
no alcian blue staining. Despite these results, Kisiel et al (Kisiel et al, 2012)
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reported unsuccessful attempts at differentiating cMSCs from different tissues
along the chondrogenic lineage. It would be interesting to validate the expression
pattern of genes associated with chondrogenic markers such as collagen type II,
aggrecan, and sex-determining region Y box 9 (SOX9) to confirm differentiation
of cMSCs towards chondrogenesis when morphological and histochemical
results remain inconclusive (Neupane et al, 2008; Seo et al, 2012; Volk et al,
2012, Vieira et al, 2010). In our study, the addition of dexamethasone and TGFβ3 to the chondrogenic medium played an important role in chondrogenesis:
TGFβ-3 works by upregulating the expression of extracellular matrix genes
(Dong et al, 2005), and dexamethasone, by also increasing the expression of
extracellular matrix genes and/or enhancing their TGFβ-3 –mediated expression
(Derfoul et al, 2006)
Neurogenesis differentiation
In our study, cMSCs were induced neurogenically for different time points
ranging from 24 hours to 4, 7, and 14 days to assess how soon they promote
formation of neuronal precursor cells. As previously reported (Kim et al, 2014;
Jang et al, 2010.) we used the two-step neurogenic induction protocol: the first
step was preinduction with fetal bovine serum and β-fibroblast growth factor (βFGF); the second step was induction phase with medium supplemented with
butylated hydroxyanisole (BHA), forskolin, valproic acid, and insulin. The purpose
of these two steps is to decrease environmental damage to cells after adding
supplemented medium for neuronal induction (Kim et al, 2014). Previous studies
have used numerous reagents to differentiate neural precursor cells such as
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dibutyryl-cyclic

adenosine

monophosphate

(db-cAMP),

3-isobutyl-1-

methylxanthine (IBMX), and retinoic acid (RA) (Tio et al, 2010); a cocktail of
IBMX, indomethacin, and insulin (Fujimura et al, 2005); neural growth factor
(Kamishina et al, 2008), and β-FGF and forskolin (Jang et al, 2010). IBMX and
db-cAMP upregulate intracellular cAMP levels, which possibly activate protein
kinase A (PKA). Wang et al (Wang et al, 2007) stated that PKA mediates neural
differentiation of human cord blood-derived MSCs. β-FGF has a substantial
capacity for neuronal differentiation by producing neuronal precursor cells.
Forskolin is a regularly used agent to upregulate the intracellular levels of cAMP,
which eventually activates the protein kinase A (PKA) signaling pathway.
Additionally, forskolin induces the neuron-like morphology and expression of
some neural specific genes in human MSCs (Jang et al, 2010).
The observed neuronal-like morphological changes in the induced cMSCs were
consistent with previous studies on cMSCs (Oda et al, 2013; Kamishina et al,
2006), umbilical cord blood and amniotic membrane-derived cMSCs (Seo et al,
2009-Q; Park et al, 2012). In fact, Kamishina et al (Kamishina et al, 2006)
reported that cMSCs had neuron-like morphologic characteristics as early as 3
hours after the induction of neural differentiation. The interpretation of the
significance of these in vitro neuronal changes should not be overestimated as
previously mentioned by other researchers (Lu et al, 2004; Neuhiber et al,
2004),. These investigators have expressed that the morphological and
immunocytochemical changes observed after neuronal induction could be the
result of cytotoxic effects of the reagents in the induction medium, which leads to
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cell shrinkage and actin cytoskeleton retraction. Also, these changes might be a
response to chemical stress, because similar cellular modifications have been
observed in the presence of Triton X-100 or sodium hydroxide (Deng et al, 2006).
We also analyzed the neural-specific proteins nestin and βIII-tubulin by
immunostaining and found that both non-induced and induced cMSCs expressed
these neuron-specific markers. The spontaneous expression of these neuralspecific proteins by cMSCs, under normal culture conditions has also been
previously reported. Deng et al (Deng et al, 2006) found that nearly 100% of mice
MSCs cultures spontaneously expressed the intermediate filament protein nestin,
In addition, the cells in their study were also positive for several neuron-specific
proteins, including βIII-tubulin and medium weight neurofilament (NFM), but
negative for the astrocyte-specific glial fibrillary acidic protein (GFAP) and
vimentin. Kamishina et al (Kamishina et al, 2006), studying neuronal
differentiation

of

cMSCs

from

iliac

crest

bone

marrow,

found

that

immunocytochemical and western blot analyses revealed that untreated cMSCs
strongly expressed βIII-tubulin and GFAP. The authors concluded that, if cMSCs
are positive for βIII-tubulin, they probably have inherent potential to differentiate
into neuronal cells under appropriate conditions.
The spontaneous attainment of neural properties by non-induced MSCs. may be
explained by the neural differentiation propensity of stem cell reflected in the
development of the nervous system during embryogenesis. Undetermined
ectoderm cells differentiate into neural lineage by default unless inhibited by
ventralizing factors, such as bone morphogenetic protein-4 (BMP4) (Wilson and
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Hemmati-Brivanlou 1995). Therefore, it is likely that MSCs, as multipotent stem
cells, may exhibit a neural property in their default state of differentiation in vitro,
where there are no pro-mesoderm inhibitors such as BMP4 (Deng et al, 2006).
Since our studies show inconsistencies in site-specific neuronal differentiation of
cMSCs, it will be more informative to examine this further at the genetic level and
with longer induction periods.

6 CONCLUSIONS
Dogs offer not only a valuable experimental model but also represent a clinically
relevant and superior animal model compared with other organisms. Previous
studies have successfully isolated cMSCs from different tissues, and in vitro
differentiation capacities have also been reported. Undifferentiated cMSCs have
been characterized morphologically, immunophenotypically, and by their gene
expression. However, in marked contrast with human MSCs, basic biology of
cMSCs is yet to be fully elucidated, and so far no uniform characterization criteria
are available for MSCs from canine origin. Only a limited number of trials have
attempted to identify a panel of cell surface markers and transcription factor
profiles for these stem cells. While the current study tested cMSCs from a
restricted number of subjects, it enhanced our understanding of cMSCs and their
skeletal site-specific characteristics. Our results demonstrated that cryopreserved
cMSCs could be expanded and differentiated, in vitro, at least into the three main
differentiation lineages: osteogenic, adipogenic, and chondrogenic, as well as
neurogenic. In addition, the impressive osteogenic potential of cMSCs, in this
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study also showed that M-cMSCs are apparently more responsive to multilineage differentiation relative to F-cMSCs. These are consistent with data from
studies using human, mouse and rat MSCs (Akintoye et al, 2006; Yoshimura et
al, 2007; Aghaloo et al, 2010; Lee et al, 2011).
One prospective future direction is to confirm these results by using a larger
population of MSC donors; therefore, the inter-animal variability would be
minimized. Since dog breeds exhibit an extremely wide range of body types, it
would be interesting to research MSCs from different canine breeds. Another
avenue of investigation of cMSCs would be the refinement of in vitro expansion
strategies as well as detailed comprehension of donor characteristics. Future
pre-clinical and clinical studies regarding cMSCs is definitely required not only to
motivate, but also to appropriately translate the potential therapeutic use of these
cells in both veterinary and human medicine.
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